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ABSTRACT 
 
      The Tec kinase ITK is activated by TCR stimulation and also required for 
TCR downstream signaling. Previous studies have reported differential roles of 
ITK and another Tec family kinase RLK in CD4+ TH differentiation and effector 
function. However, these findings are confounded by the complex T cell 
developmental defects in Itk-/- mice. Furthermore, the function of ITK in tissue-
resident T cells in the intestine and anti-viral immune response to a persistent 
infection has not been studied previously. In addition to T cells, recent studies 
have indicated an expression of ITK in ILC2, but not in other ILC subsets. Yet, 
the role of ITK in ILC2 has not been characterized. 
      Here, I have examined the role of ITK and RLK in CD4+ TH subsets using a 
small molecule inhibitor PRN694. I found that PRN694 impaired TH1 
differentiation in vitro, and PRN694 administration prevented TH1-mediated colitis 
progression in vivo. In an MHV68 infection model, Itk-/- mice failed to control viral 
replication in the intestine, while gut-homing of CD8+ T cells was greatly impaired. 
Finally, I found that ILC2 number was markedly reduced in the intestine of Itk-/- 
mice. Gut-specific defect of Itk-/- ILC2 is associated with a low availability of IL-2 
in the intestine of Itk-/- mice. Collectively, these data suggest that ITK is important 
in T cell migration to the intestine and ILC2 homeostasis in the intestine, thereby 
contributing to the protective response to a latent virus and intestinal tissue 
homeostasis. 
 vii 
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CHAPTER I: INTRODUCTION 
 
A. TCR-mediated signaling and the Tec family kinases 
T cells are a key component of the adaptive immunity to mount an effective 
immune response to various pathogens. T cells have an antigen receptor called 
T cell receptor (TCR) that specifically recognizes an array of peptides presented 
on major histocompatibility complex (MHC) molecules (Smith-Garvin et al., 
2009). Upon engagement of the TCR with a cognate peptide, this interaction 
promotes the phosphorylation of immunoreceptor tyrosine-based activation 
motifs (ITAMs) in the intracellular domain of CD3 by the Src family protein 
tyrosine kinase LCK bound to CD4 or CD8 co-receptors (Andreotti et al., 2010; 
Berg et al., 2005). The phosphorylation of CD3 ITAMs leads to the recruitment of 
another important protein kinase ZAP-70, and LCK activates ZAP-70 (Fowell et 
al., 1999; Gomez-Rodriguez et al., 2009; 2014; Miller et al., 2004; Schwartzberg 
et al., 2005). A major function of ZAP-70 is to phosphorylate a scaffolding 
transmembrane protein linker for activation of T cells (LAT), and this 
phosphorylation generates docking sites to recruit multiple adaptor proteins, such 
as the SH2-domain-containing leukocyte protein of 76 kDa (SLP-76) to the LAT 
linker protein (Fowell et al., 1999; Gomez-Rodriguez et al., 2009; Jain et al., 
2013; C. Mueller and August, 2003; Schaeffer et al., 2001). 
      The Tec family kinases are comprised of five nonreceptor tyrosine kinases: 
tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton’s tyrosine 
kinase (BTK), IL-2-inducible T cell kinase (ITK), resting lymphocyte kinase (RLK), 
 3 
and epithelial and endothelial tyrosine kinase (ETK) (Cho et al., 2015; Kannan et 
al., 2015b). Among these family kinase members, T cells mainly express three 
Tec kinases, ITK, RLK, and TEC, and ITK is the most predominantly expressed 
(Masopust et al., 2010; S. N. Mueller and Mackay, 2016; Shin and Iwasaki, 
2013). In the TCR signaling complex, ITK interacts with the SLP-76/LAT adaptor 
complex via its Src homology domains. When ITK is activated by LCK 
phosphorylation (Y511) at the activation loop (Johansson-Lindbom et al., 2005; 
2003; Mora et al., 2003; 2005), ITK subsequently undergoes cis-
autophosphorylation (Y180) at SH3 domain (Mackay et al., 2013; Skon et al., 
2013). Once activated, ITK phosphorylates its downstream substrate, 
phospholipase C (PLC) γ1, and the major enzymatic function of activated PLCγ1 
is to hydrolyze phosphatidylinositol 4,5-biphosphate (PIP2) to produce two 
byproducts, diacylglycerol (DAG) and inositol triphosphate (IP3) (N. Zhang and 
Bevan, 2013). These two byproducts, DAG and IP3, work as secondary 
messengers to regulate further downstream signaling including Ca2+ influx, 
RasGRP-ERK activation, and PKC-θ activation, which consequently lead to T 
cell full activation (Man et al., 2017; 2013; Yao et al., 2013) (Fig. 1.1). 
      Previous studies showed that Itk deficiency in T cells greatly impairs the 
magnitude of T cell activation. However, unlike Src family kinases (e.g. LCK or 
FYN) in T cells, ITK is not absolutely required for all TCR downstream responses 
owing to a partial redundancy in ITK function with other Tec kinase RLK as Itk-/- 
Rlk-/- T cells are more impaired in TCR signaling than Itk-/- T cells (Iwata et al.,  
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Figure 1.1. TCR-mediated signaling and the function of ITK 
Upon TCR engagement with peptide-MHC, active LCK phosphorylates the 
ITAMs, ZAP-70, and ITK. This initial signaling event leads to the phosphorylation 
of SLP-76 and LAT by ZAP-70. Phosphorylated ITK (Y180 and Y511) then 
activates its downstream target PLCγ1. The primary enzymatic function of PLCγ1 
is to hydrolyze its major substrate PIP2, which leads to the production of two 
secondary messengers, DAG and IP3. These secondary messengers eventually 
result in the activation of RasGRP-ERK pathway and Ca2+ influx, which in turn 
activate AP-1, NK-κB, and NFAT activation in T cells. 
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2017; Krishnamoorthy et al., 2017; Man et al., 2017; 2013; Shi et al., 2014). 
However, mRNA expression of RLK is lower at 3- to 10-fold than ITK mRNA 
expression, and the precise of role of RLK in T cell activation is unclear (Nayar et 
al., 2012). Together, these data suggest that the function of ITK in T cell 
activation is to amplify TCR signaling strength, rather than to work as an on-and-
off switch.    
 
B. Role of ITK in CD4+ T cell differentiation and immune diseases 
Early studies on ITK function have reported that ITK plays a critical role in CD4+ T 
cell differentiation and effector function. These studies showed that CD4+ T cells 
from Itk-/- mice impaired in TH2 differentiation, and Itk-/- mice exhibited a reduced 
production of TH2 cytokines against parasitic infection, e.g. Schistosoma mansoni 
or Nippostrongylus brasiliensis (Kumar et al., 2017; Wakim et al., 2012). In 
contrast, Itk deficiency has a minimal effect on the TH1 response to intracellular 
protozoans, such as Leishmania major (Guérin et al., 2017). These data indicate 
that ITK has a more crucial role for TH2-mediated response than for TH1-
mediated response.  
      In addition to the role of ITK in TH2-mediated immunity, Schwartzberg and 
colleagues reported an additional role of ITK in TH17 differentiation (Barton et al., 
2011). Specifically, Itk-/- CD4+ T cells showed a diminished IL-17A production 
while forkhead box P3 (Foxp3) expression was increased under TH17-polarizing 
condition (Sunil-Chandra et al., 1992). In an adoptive transfer model of colitis, 
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transferred Itk-/- colitogenic CD4+ T cells (CD25- CD45RBhi) in Rag1-deficient 
lymphopenic hosts showed more conversion to Fopx3-expressing regulatory T 
cells (Treg) than WT colitogenic CD4+ T cells while ITK does not affect the 
suppressive function of Treg (Barton et al., 2011). However, August and 
colleagues showed that Itk-/- Treg failed to protect colitogenic T cell-mediated 
colitis in the colon and thus argue that ITK regulates the function of Treg (Sunil-
Chandra et al., 1992). Lastly, a recent study from Schwartzberg and colleagues 
showed that ITK works as a positive regulator for TH9 differentiation via IL-2 and 
ITK downstream transcription factor interferon regulatory factor 4 (IRF4) 
(Peacock and Bost, 2000). Despite of some disparities between studies, these 
studies suggest that ITK regulates the differentiation and also effector function of 
various CD4+ TH subsets.    
 
C. Role of ITK in CD8+ T cells and anti-viral immunity 
Comparing with the studies on the role of ITK in CD4+ T cells, fewer studies have 
demonstrated the role of ITK in CD8+ T cells in pathogen infections. In the 
absence of ITK, cytotoxic T cell (CTL) activity was reduced after lymphocytic 
choriomeningitis virus (LCMV), vaccinia virus (VV), and vesicular stomatitis virus 
(VSV) infection (Milho et al., 2009). In TCR-mediated signaling, Itk-/- CD8+ T cells 
are impaired in the phosphorylation of PLCγ1, ERK1/2, and p38 MAPK and 
effector cytokine production in response to anti-CD3 stimulation (Hwang et al., 
2008). In spite of these CD8+ T cell defects, Itk-/- mice mount a normal protective 
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response to acute infection with LCMV, VV, and VSV while the kinetics of virus 
control in Itk-/- mice was modestly delayed (Guérin et al., 2018). Although Itk-/- 
mice exhibited more memory precursor effector cells (KLRG-1lo IL-7Rαhi) at an 
early time of Listeria monocytogenes infection, both WT and Itk-/- memory CD8+ T 
cells showed comparable recall response (Cho et al., 2015; Zhong et al., 2015). 
However, it remains to be determined whether Itk-deficient CD8+ T cells can 
generate a functional memory T cells against virus infection. These data 
suggested that, unlike CD4+ T cells, CD8+ T cells might be less reliant on ITK-
mediated signaling to generate a robust CD8+ T cell effector response. 
 
D. Human and mouse gammaherpesvirus infection 
Gammaherpesviruses are lymphotropic double-stranded DNA viruses that 
establish a life-long infection in memory B cells in the spleen. Human 
gammaherpesviruses, such as Epstein-Barr virus (EBV) and Kaposi’s sarcoma-
associated herpesvirus (KSHV), are associated with the development of 
lymphoproliferative disease, lymphoma, and non-lymphoid cancers (Gredmark-
Russ et al., 2008). Gammaherpesviruses initially infect the mucosal tissues and 
then undergo viral replication before establishing viral latency in B cells or 
macrophages. Due to their narrow host tropism of EBV and KSHV, murine 
gammaherpesvirus 68 (MHV68) is broadly recognized as a model to recapitulate 
the pathogenesis of gammaherpesvirus infection in mice (Atherly et al., 2006b; 
Bachmann et al., 1997). Following MHV68 infection in mice, predominant sites of 
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viral replication are determined mostly by the route of infection. For 
intraperitoneal (IP) infection, the spleen is the major site of viral replication, 
whereas viral replication in the lung predominates following intranasal (IN) 
infection (Gargano et al., 2009). By 14-16 days of post-infection via 
intraperitoneal injection, the acute viral infection is controlled, and viral replication 
in the spleen becomes nearly undetectable (Nayar et al., 2012). In addition to 
these routes of infection, gastric instillation of MHV68 has been shown to lead to 
persistent viral replication in intestinal epithelium (Man et al., 2013; Nayar et al., 
2014). By using a recombinant MHV68 constructed to express a firefly luciferase 
driven by the viral M3 promoter, several studies have demonstrated that MHV68 
readily replicates in the gastrointestinal tract via IP infection at an early phase of 
infection (D4), and viral replication in the peritoneum can be detected until D30 of 
post-infection (Nayar et al., 2012; Zheng et al., 2009).  
 
E. ITK and human immunodeficiency in EBV infection 
Several clinical studies have reported that genetic alterations in ITK causes a 
lethal lymphoproliferative disease due to a failure to control EBV infection in 
young adults (Khanna et al., 2003; Knickelbein et al., 2008; Liu et al., 2001; 
Sheridan et al., 2014). As ITK mutations have never been found in other 
lymphoproliferative disorders, e.g. hemophagocytic lymphohistiolysis, 
autoimmune lymphoproliferative syndrome, or common variable immune 
deficiency, lymphoproliferation observed in EBV patients is most likely caused by 
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a failure to control EBV infection. Furthermore, ITK mutations found in EBV 
patients were sufficient to destabilize the half-life of protein and also impede ITK 
recruitment to the membrane to interact with PIP2 (Casey et al., 2012). In 
contrast to these findings, Itk deficiency in mice did not impact on anti-viral 
immune response to acute virus infections (Bein et al., 2017; Guo et al., 2015). 
Yet, no studies have shown a precise role of ITK in anti-viral T cell response to a 
latent or a persistent virus infection such as gammaherpesvirus.  
 
F. Tissue-resident memory CD8+ T cells and T cell migration to the intestine 
Mucosal tissues, such as skin, lung, intestine, and genital tract, are the major 
portals of pathogen entry, thus serving as protective barriers against invading 
pathogens (Onyeagocha et al., 2009). To protect the host, invading pathogens at 
these mucosal barriers must be immediately and efficiently controlled by immune 
response. To achieve this goal, a variety of tissue-resident lymphocyte subsets 
and innate lymphoid cell (ILC) subsets are residing at the mucosal barriers in a 
steady-state. Among these tissue-resident immune cells, tissue-resident memory 
CD8+ T cells (TRM) have an integral role to elicit a protective response to the 
infection with microbes and viruses (Bein et al., 2017; Guo et al., 2015). 
      For T cell trafficking to the intestine, effector CD8+ T cells acquire the ability to 
enter into intestinal tissue by expressing gut-homing receptors during their 
activation. Integrin α4β7 and CCR9 are induced by all-trans retinoic acid (RA)-
producing dendritic cells (DCs) in mesenteric lymph node (mLN) or Peyer’s 
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patches (Mokrani et al., 2014). After entry into the intestinal epithelium, CD8+ T 
cells upregulate the activation marker CD69 and the integrin CD103 (integrin αE), 
while downregulating CCR7 and sphingosine-1-phosphate receptor 1 (S1PR1) to 
prevent tissue egress, thereby adopting a TRM phenotype (Fowell et al., 1999). 
Transforming growth factor-β (TGF-β), ubiquitously expressed throughout the 
intestinal mucosa, promotes the expression of CD103, and thereby plays a key 
role in promoting T cell tissue retention (Zloza et al., 2011). 
 
G. Role of IRF4 in CD8+ T cells and tissue residency of T cells 
The transcriptional regulator interferon regulatory factor 4 (IRF4) has a multitude 
of functions in T cells (Kumar et al., 2017; Landrith et al., 2017; Wakim et al., 
2012). In both CD4+ and CD8+ T cells, IRF4 serves as a molecular link that 
translates TCR signal strength to transcriptional changes affecting T helper cell 
and Treg differentiation and effector cytotoxic T cell differentiation 
(Vasanthakumar et al., 2015). Consistent with its functional relevance with TCR 
signaling, IRF4 was identified as a direct downstream target of ITK from 
microarray data (Iwata et al., 2017; Kurachi et al., 2014; P. Li et al., 2012). As a 
transcription factor to bind the target genes, IRF4-mediated transcription in T 
cells is cooperatively regulated by basic leucine zipper ATF-like transcription 
factor (BATF) and activator protein 1 (AP-1) (Wang et al., 2013). 
      Interestingly, recent studies have revealed that IRF4 is highly expressed in 
CD69-expressing TRM from human lung tissue and also in adoptively transferred 
 11 
CD103+ OT-I TCR transgenic T cells in the brain after Ovalbumin (OVA)-
expressing Listeria monocytogenes infection (Nayar et al., 2012). Although 
BATF-IRF4 is required for visceral adipose tissue (VAT) Treg development 
(Guérin et al., 2017), the role of IRF4 in mucosal tissue residency of T cells or in 
tissue homing to non-lymphoid tissues have not been studied.  
 
H. Innate lymphoid cells and type 2 innate lymphoid cells 
Innate lymphoid cells are one of the lymphocyte subsets that lacks an antigen-
specific receptor; yet, these cells produce effector molecules shared with those 
produced by CD4+ T helper cells (Nayar et al., 2012). The function of ILCs are 
involved in tissue remodeling, anti-microbial immunity, and allergic inflammation 
at mucosal barriers. Their unique positioning at mucosal barriers confers a 
strategic advantage to ILC, allowing them to respond promptly to tissue 
perturbations caused by bacterial or viral infections (Smith et al., 2006). ILC 
subsets can be categorized into two major categories: cytotoxic ILC, such as 
conventional NK cells, and non-cytotoxic helper-like ILC, such as ILC1, ILC2, and 
ILC3. Each ILC subset expresses a key transcription factor that regulates a 
distinct cytokine profile corresponding to their adaptive CD4+ T cell counterparts: 
T-bet for ILC1, GATA-3 for ILC2, and RORγt for ILC3 (Sunil-Chandra et al., 
1992). 
      Among ILC subsets, type 2 innate lymphoid cells (ILC2) were first identified in 
mesenteric fat-associated clusters and later demonstrated to be positioned in the 
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bone marrow, lung, liver, skin, thymus, and intestinal lamina propria (Iwata et al., 
2017; Kurachi et al., 2014). ILC2 express a set of phenotypic markers, such as 
CD90, CD127, CD25, CD117, IL-25R, IL-33R (T1/ST2), along with ILC2 
signature transcription factor, GATA-3 (Robinson et al., 2011). Upon stimulation 
by IL-25, IL-33, and thymic stromal lymphoprotein (TSLP), ILC2 produce IL-5, IL-
9, IL-13, and amphiregulin (Areg), which are important effector molecules during 
intestinal helminthic infection and also promote epithelial growth from a tissue 
damage caused by virus infections in the lung (Monticelli et al., 2015; 2011; 
Wilhelm et al., 2011). In addition to IL-25, IL-33, and TSLP, IL-2 plays an 
important role in the effector function of ILC2 to produce IL-5 and IL-9, and IL-
2/anti-IL-2 complex is known to induce in vivo proliferation of ILC2 (Roediger et 
al., 2013; Seehus et al., 2017).  
 
I. Intestinal tissue migration of innate lymphoid cells 
Innate lymphoid cells develop from their lymphoid progenitors in fetal liver and 
adult bone marrow (BM) and disseminate to various peripheral tissues 
(Constantinides et al., 2014; Serafini et al., 2014). ILC precursors express 
integrin α4β7, which is a homing receptor that binds to mucosal vascular 
addressin cell adhesion molecule 1 (MAdCAM-1), highly enriched in endothelium 
of gut-associated lymphoid tissues (Klose et al., 2014). Furthermore, ILC 
precursors express CCR9, a key homing receptor molecule that guides cells to 
intestinal tissues (M. H. Kim et al., 2015). Previous studies demonstrated that RA 
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upregulates the expression of integrin α4β7 and CCR9 in ILC1 and ILC3 for 
intestinal tissue migration. Unlike ILC1 or ILC3, immature BM ILC2 precursors 
(ILC2P) are programmed to express high levels of these gut-homing receptors 
(M. H. Kim et al., 2015). This indicates that intestinal tissue migration of ILC2 is 
RA-independent. Dissemination of ILC2 to the peripheral tissues also requires 
efficient egress of BM ILC2 precursors from the bone marrow. Stier et al. recently 
reported that IL-33/IL-33R signaling is important for ILC2P to downregulate 
CXCR4, a tissue retention marker in the BM (Stier et al., 2018). This study 
showed that ILC2P from St2-/- mice expressed higher levels of CXCR4, 
concomitantly with an accumulation of ILC2P in the BM (Stier et al., 2018). These 
findings suggested that the trafficking of ILC2 from their precursors arising in the 
BM to their home in peripheral tissue sites is a cooperative process combining 
successful tissue egress with proper tissue homing.  
 
J. ITK expression in innate lymphoid cells 
Despite a lack of antigen-specific receptors, ILC express a set of TCR-associated 
signaling mediators, such as LAT, LCK, ICOS, and ITK (Constantinides et al., 
2014; Harly et al., 2018; Hoyler et al., 2012; Klose et al., 2014; Yang et al., 
2015). Transcriptome analysis in ILCs revealed that innate lymphoid cells have 
more similarities with T cells than with other adaptive lymphocytes 2, but a 
precise role of TCR signaling molecules in ILC has not been previously 
characterized. Interestingly, a recent study from Shih et al. reported that ITK and 
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IRF4, a downstream transcription factor of TCR-mediated signaling, were found 
among the most highly upregulated genes regulating the development and 
function of ILC2 (Shih et al., 2016). Consistent with this finding, RNA-seq data 
from the Immunological Genome Consortium (www.immgen.org) shows that Itk 
expression is highly elevated in ILC2 compared to other ILC subsets. 
Interestingly, in addition to its role in TCR signaling, ITK is known to be important 
for CD4+ T cell migration to the intestine. However, the role of ITK in type 2 innate 
lymphoid cells has never been assessed.     
 
K. Thesis objectives 
The complex phenotype of Itk-/- mice, including defects in T cell development, 
activation, differentiation, and effector function, has made it difficult to precisely 
assess the function of ITK in each lineage of T cells and at different stages of an 
immune response. It has also been challenging to distinguish functions of ITK in 
T cell activation and differentiation from effects due to altered T cell development 
in Itk-/- mice. A more direct strategy to address ITK and/or RLK function in T cells 
is to utilize a selective small molecule inhibitor of these Tec kinases. PRN694 is a 
small molecule that forms an irreversible covalent bond with C442 in ITK or C350 
in RLK, and has recently been shown to selectively inhibit ITK and RLK in T cells 
(Zhong et al., 2015). In Chapter III of this thesis, I examined the inhibitory effects 
of PRN694 on CD4+ T helper cell differentiation and effector function in vitro and 
in vivo. 
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In contrast to EBV-associated lymphoproliferation in the patients who have 
ITK mutations due to a failure in controlling viral replication (Ghosh et al., 2014; 
Huck et al., 2009; Linka et al., 2012; Mansouri et al., 2012; Stepensky et al., 
2011), Itk-deficient mice mounted a comparable anti-viral CD8+ T cell response 
with WT mice to acute viral infections (Atherly et al., 2006b; Bachmann et al., 
1997). I considered whether this discrepancy might be accounted for by a 
previously unexplored role for ITK in maintaining long-term viral latency in the 
case of a persistent viral infection. In Chapter IV of this thesis, I examined the 
responses of Itk-/- mice to MHV68 as a mouse model for human 
immunodeficiency to address the potential requirement for ITK in protective 
immunity to persistent herpesvirus infections.  
Based on the gene expression analysis of innate lymphocyte populations 
(www.immgen.org), ITK is highly upregulated in intestinal ILC2, but not in other 
ILC subsets. Although Itk-/- mice showed a modest defect in ILC2 function upon 
papain sensitization in the lung (Gomez-Rodriguez et al., 2016), a precise role of 
ITK in ILC2 or the molecular mechanism of ITK-associated ILC2 defect has not 
clearly demonstrated. In Chapter V of this thesis, I examined the role of ITK in 
ILC2 in the intestine and also in intestinal tissue integrity related to ILC2 defect in 
Itk-/- mice. 
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CHAPTER II: MATERIALS AND METHODS 
 
Materials and Methods for the experiments in Chapter III 
A. Mice 
For PRN694 effect on CD4+ T cell study in Chapter III, C57BL/6 WT, C57BL/6 
Rag2-/-, C57BL/6 OT-II Rag1-/- TCR transgenic (Tg), and B10.A 5C.C7 Rag2-/- 
TCR Tg mice were purchased from Taconic Biosciences and housed in specific-
pathogen-free (SPF) conditions at University of Massachusetts Medical School 
(UMMS) in accordance with Institutional Animal Care and Use Committee 
(IACUC) guidelines. For some experiments performed in Principia Biopharma, 
C57BL/6 WT were purchased from Charles River Laboratories. All housing and 
procedures with these mice were in accordance with the guidelines approved by 
IACUC of Principia Biopharma.  
 
B. Antibodies and reagents for flow cytometric analysis 
Cells were stimulated with PMA (50 ng/mL) and Ionomycin (1.0 μg/mL) for 5 h 
with protein transport inhibitors, GolgiStop™ and GolgiPlug™ (BD Biosciences), 
each at 1.0 μg/mL. All cells were first stained with antibodies to CD4 (GK1.5) and 
CD44 (IM7) (BD Biosciences), and LIVE/DEAD® Fixable Aqua Dead Cell Stain 
Kit (Life Technologies). Stained cells were then fixed and permeabilized by using 
BD Cytofix/Cytoperm™ Kit (BD Biosciences). For intracellular cytokine staining 
(ICS), cells were stained with antibodies to IFN-γ (XMG1.2), IL-4 (11B11), IL-17A 
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(N49-653), or IL-2 (7D4) (BD Biosciences and eBioscience). For transcription 
factor staining, cells were fixed and permeabilized using Foxp3/Transcription 
Factor Staining Buffer Set (eBioscience), and stained with antibodies to T-bet 
(4B10), GATA-3 (TWAJ), RORγt (B2D), or Foxp3 (FJK-16s) (BD Biosciences 
and eBioscience).  
 
C. T helper cell polarization and CFSE dilution assay 
Naïve CD4+ T cells (3.0 x 105) from B10.A 5C.C7 Rag2-/- TCR Tg or C57BL/6 OT-
II Rag1-/- TCR Tg mice were isolated using CD4 (L3T4) MicroBeads (Miltenyi 
Biotec). Isolated cells were plated in 12- or 24-well plates and activated by plate-
bound anti-CD3 (1.0 μg/mL) and anti-CD28 (4.0 μg/mL) (BD Biosciences) for 72 
h in the presence of following conditions: TH0 (anti-CD3/CD28 with no cytokines); 
TH1 (IL-12, 10 ng/mL plus anti-IL-4, 10 μg/mL); TH2 (IL-4, 10 ng/mL plus anti-IFN-
γ, 10 μg/mL); TH17 (IL-6, 20 ng/mL, TGF-β, 5.0 ng/mL, IL-1β, 20 ng/mL, plus 
anti-IFN-γ, anti-IL-4, and anti-IL-2, each at 10 μg/mL) (all cytokine neutralizing 
antibodies were purchased from R&D Systems and BD Biosciences). For CFSE 
dilution assay, CD4+ T cells isolated by magnetic separation were resuspended in 
1.0 mL of 1X PBS with 0.1% BSA at 5.0 x 106 cells/mL. Then, cells were stained 
with CFSE at a final concentration of 2.0μM at 37°C for 10 min. After incubation, 
stained cells were quenched by adding 5 volume of ice-cold RPMI 1640 
complete medium (10% FBS) for 5 min on ice. Cells were washed three times 
with complete medium and then plated for TH polarization for 72 h. 
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D. Mouse adoptive transfer colitis and PRN694 administration 
CD4+ CD45RBhi T cells were sorted from spleens of B6 WT mice and 4.0 x 105 
cells were injected IP into C57BL/6 Rag2-/- hosts. Recipient mice were weighed 
daily and sacrificed 7 weeks post-transfer, at which time colons were removed for 
length measurement, histologic analysis, and lymphocyte isolation, and lymphoid 
organs harvested for flow cytometry analysis. Vehicle (5% ethanol/95% Captex 
355 EP/NF, ABITEC) or PRN694 was orally administered according to the 
following regimen: once a day (40 mg/kg) for weeks 0-2 and 4-7, and twice a day 
(20 mg/kg) for weeks 2-4.  
 
E. In vivo PRN694 target engagement assay 
Naïve B6 mice were dosed with vehicle or PRN694 (40 mg/kg). After 2 h or 6 h of 
oral administration, the dosed mice were sacrificed, and CD4+ T cells were 
isolated from the spleen by using EasySepTM Mouse CD4+ T cell Isolation Kit 
(StemCell Technologies). Then, isolated CD4+ T cells were stimulated with anti-
CD3 (10 µg/mL) and anti-CD28 (5.0 µg/mL) for 5min at 37˚C. After stimulation, 
CD4+ T cells (4.0 x 106) were lysed by CelLytic M buffer (Sigma-Aldrich) 
containing proteinase and phosphatase inhibitor. The expression of 
phosphorylated-PLCγ1 and total PLCγ1 was examined by western blot using 
anti-p-PLCγ1 (Tyr783) mAb and anti-PLCγ-1 mAb (D9H10) (Cell Signaling) at 
1:1000 dilution. The secondary antibody was AlexaFluor647-conjugated anti-
rabbit IgG (H+L) (Invitrogen) at 1:1000 dilution, and the signal was evaluated 
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using Typhoon Biomolecular Imager (GE Healthcare Life Sciences) with signal 
quantification using ImageQuant TL 7.0 software (GE Healthcare Life Sciences). 
 
F. Isolation of lymphocytes from the intestine 
Intestinal tissues were opened longitudinally and cut into 1-2 cm pieces. Tissues 
were treated with 1 mM DTT in HBSS at 37°C for several rounds. Supernatants 
were collected for intraepithelial lymphocytes (IEL) isolation. For lamina propria 
lymphocytes (LPL) isolation, the remaining tissues were digested with a mixture 
of collagenase D (1.0 mg/mL, Roche), neutral protease (0.1 U/mL, Worthington 
Biochemical), and DNase I (1.0 U/mL, Sigma-Aldrich) for 40-50 min (small 
intestine) or 50-60 min (colon). Cell suspensions were layered on 40%/80% 
Percoll (GE Healthcare Life Sciences) density gradients for lymphocyte 
isolations. The viability of extracted cells was assessed using trypan blue.  
 
G. P-selectin binding and cell migration assays 
Naïve CD4+ T cells were isolated with CD4 (L3T4) MicroBeads (Miltenyi Biotec) 
and then cultured in the presence or absence of PRN694 (25 or 50nM) for 72 h in 
each TH polarization condition as described above. For P-selectin binding assay, 
cultured and polarized CD4+ T cells were first treated with 2.4G2 Fc block (anti-
CD16/CD32) for 10 min at 4°C and then washed with FACS buffer (1X PBS 
containing 5.0% FBS). Recombinant P-selectin-human IgG fusion protein 
(eBioscience) was added to the cells (1:200 dilution) at 4°C for 30 min. Cells 
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were washed, then stained with APC-conjugated anti-human IgG (Jackson 
ImmunoResearch Laboratories) and surface marker antibodies. The cell 
migration assay was performed by using HTS Transwell-96 well permeable 
supports with 3.0 μm pore (Corning). Cultured CD4+ T cells were washed twice 
and resuspended at 2.5 x 106 cells/mL with serum-free RPMI 1640 containing 
0.1% BSA. Lower chambers were loaded with 200 μL of diluted chemokines 
(CXCL11 100 ng/mL; CCL20 100 ng/mL; CCL25 300 ng/mL) (PeproTech and 
R&D Systems). 25 μL of cell suspension (5.0 x 105 cells) was loaded in the upper 
chamber polycarbonate filter. Cell migration was performed at 37°C, 5% CO2 for 
3 h, and non-migrated cells on the upper chamber were rinsed off with 1X PBS 
containing 0.1% BSA. After centrifugation (1500 rpm for 10 min), the upper 
chamber was removed, and the migrated cells were resuspended in 1X PBS with 
0.1% BSA. The numbers of migrated cells were counted by the flow cytometer. 
To calculate the chemotaxis index, the numbers of cells migrated in response to 
each chemokine were divided by the numbers of spontaneously migrated cells. 
 
H. Histologic examination of colon 
Colon specimens obtained from vehicle-treated or PRN694-treated hosts were 
fixed in 10% buffered formalin and stained with hematoxylin and eosin. To 
assess the severity of colitis, histologic scores of the proximal, middle, and distal 
colon were examined.  
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Materials and Methods for the experiments in Chapter IV 
A. Mice 
C57BL/6 WT, Rag1-/-, Rag2-/-, congenic Ly5.1 (CD45.1), and OT-I Rag1-/- TCR 
Tg mice were purchased from Taconic Biosciences and crossed with Itk-/- to 
generate mice used for experiments. All purchased mice were housed and 
maintained with Itk-/- for several generations before experiments. Irf4fl/fl x CD4-Cre 
were described previously (Nayar et al., 2014). Mice were housed in SPF 
conditions at the UMMS in accordance with IACUC guidelines. All uninfected 
mice were analyzed at 8- to 10-week of age. For MHV68 experiments, mice were 
infected at 8- to 10-week of age and analyzed at indicated time points post-
infection.  
 
B. Antibodies and reagents for flow cytometric analysis 
Cells from the spleen, mLN, lung, bone marrow (BM), and small and large 
intestine were stained with anti-mouse CD3 (145-2C11), CD4 (RM4.5), CD8α 
(53-6.7), CD19 (6D5), CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD69 (H1.2F3), 
CD103 (M290), CD199 (eBioCW-1.2), integrin α4β7 (DATK32), KLRG-1 (2F1), 
TCRβ (H57-597), TCRγδ (eBioGL3), IRF4 (3E4) (from eBiosceince, BD 
Biosciences, and Invitrogen). In some experiments, cells were stimulated with 
viral antigenic peptide ORF75c (KSLTYYKL) or the combination of PMA (50 
ng/mL) and Ionomycin (1.0 μg/mL) for 5 h at 37￮C in the presence of GolgiStop™ 
and GolgiPlug™ (BD Biosciences). After stimulation, cells were fixed and 
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permeablized using BD Cytofix/Cytoperm Kit (BD Biosciences) to stain 
intracellular cytokines by using following antibodies: anti-mouse IFN-γ (XMG1.2), 
IL-2 (JES6-5H4), TNF-α (MP6-XT22), granzyme B (GB12) (from eBioscience, BD 
Biosciences, and Invitrogen). 
 
C. MHV68 strains, infection, and LPS-induced viral reactivation 
Mice were infected with MHV68 via IP injection (1.0 x 106 PFU/mouse) or, where 
indicated, by IN infection (1.0 x 103 PFU/mouse). For reactivation from latency, a 
single subclinical dose of LPS (20 μg) was injected IP MHV68-M3-OVA was 
engineered to express chicken ovalbumin (Smith et al., 2006). All viral stocks 
were propagated in Vero or NIH 3T3 cells and viral titers were determined by 
plaque assay as previously described (Sunil-Chandra et al., 1992). 
 
D. Viral DNA copy number measurement via q-PCR 
To examine viral replication, organs were washed with PBS and cut into 2-3 cm 
pieces. Tissues were digested with lysis buffer (100 mM Tris-HCl at pH 8.0, 0.5 
mM EDTA, 0.2% SDS, and 200 mM NaCl) mixed with proteinase K (20 μg/mL) 
(Sigma-Aldrich) at 55￮C overnight with rotation, and DNA was isolated after 
phenol:chloroform extraction. For viral copy number determination, DNA samples 
were subjected to quantitative PCR specific for viral gene ORF75c, and values 
were compared to a standard curve generated using a plasmid containing 
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ORF75c. PCR primers were 5′-AAA TGG TGA AAG CCA TTT TGA-3′ (forward) 
and 5′-CCA CCA TCG CAT AAC AGT TG-3′(reverse). 
 
E. Dendritic cell and T cell co-culture 
For DC isolation, spleens and mLNs were isolated and digested by an enzyme 
cocktail of Collagenase D (1.0 mg/mL, Roche) and DNase I (0.1 mg/mL, Sigma-
Aldrich) for 20 min at 37°C. After tissue digestion, cell suspensions were washed 
with MACS Running Buffer (2.0 mM EDTA and 0.5% BSA) twice to quench the 
reaction. DCs were purified using mouse CD11c MicroBeads UltraPure Kit 
(Miltenyi Biotec) according to the manufacturer’s protocol. DCs (1.0 x 106 cells) 
were pulsed with two different concentrations (5.0 pM, low; 200 pM, high) of T4-
OVA peptide (SIITFEKL) for 1 h at 37°C. Peptide-pulsed DCs were plated in 
round-bottom 96-well plates and co-cultured with OT-I T cells at a 1:10 ratio (DC 
: T) for 48 h, with or without PRN694 inhibitor (50nM) (Principia Biopharma), and 
then analyzed for gut-homing molecule induction. 
 
F. OT-I adoptive transfer to MHV68-M3-OVA-infected hosts 
Splenic CD8+ T cells of OT-I WT (CD45.2) and Itk-/- (CD45.1) uninfected donor 
mice were isolated using EasySep™ Mouse CD8+ T cell Isolation Kit (STEMCELL 
Technologies) according to the manufacturer’s instructions. 5.0 x 105 cells were 
injected i.v. into congenic hosts which were then infected with MHV68-M3-OVA-
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infected (1.0 x 106 PFU, IP). Mice were sacrificed at D7 post-infection for 
analysis.  
 
G. RNA isolation, reverse transcription, and q-PCR 
Total RNA was isolated with TRIzol (Life Technologies) following the 
manufacturer’s instructions. cDNA was synthesized with iScript cDNA Synthesis 
Kit (Bio-Rad) and q-PCR was performed with iQ™SYBR® Green PCR Supermix 
(Bio-Rad). Primer sequences used for q-PCR were as follows: Tgfbr2, forward 
primer (FP), 5′-AGC ATC ACG GCC ATC TGT G-3′; Tgfbr2 reverse primer (RP), 
5′-TGG CAA ACC GTC TCC AGA GT-3′; Rara FP, 5′-TCA TGA AGT GTG ACG 
TTG ACA TCC GT-3′; Rara RP, 5′- TTG GCA AGG CAA AGA C-3′; ActB FP, 5′-
CGC CAC CAG TTC GCC ATG G-3′; ActB RP, 5′-TAC AGC CCG GGG AGC 
ATC GT-3′. 
 
H. Short-term T cell migration assay 
Isolated splenic OT-I WT and Itk-/- T cells were stimulated in vitro with plate-
bound anti-CD3 (1.0 μg/mL, eBioscience) in the presence or absence of TGF-β 
(5.0 ng/mL, R&D Systems) and all-trans retinoic acid (10 nM, Sigma-Aldrich) for 
48 h. An equal number (6.0 x 106) of each OT-I population was injected i.v. into 
congenic WT hosts. At D3 of post-transfer, mice were sacrificed and adoptively 
transferred cells were analyzed by flow cytometry. 
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I. Immunohistochemistry and immunofluorescence microscopy 
For immunohistochemistry, dissected tissues were fixed in 10% buffered formalin 
(Fisher Scientific) overnight and then embedded into paraffin block for H&E 
staining. For immunofluorescence staining, collected tissues were embedded in 
Tissue-Tek® O.C.T. compound (Sakura® Finetek) and snap frozen on methanol 
mixed with dry ice. Frozen tissues were cut into 7 μm-thick sections, air-dried for 
1 h at RT and then fixed in acetone for 10 min at 4￮C. After drying for 1 h at RT, 
tissue sections were rehydrated with PBS with 1.0% BSA and then stained 
overnight with primary antibodies diluted in PBS containing 1.0% BSA, 2.0% 
normal rat serum, and 2.0% mouse serum in a humidified chamber. Sections 
were washed with PBS 3 times and then stained for secondary for 1h at RT. After 
washing, tissues were counterstained with DAPI-including ProLong™ Gold 
antifade reagent (Invitrogen) for confocal microscopy. Immunofluorescent 
antibodies and secondaries were anti-mouse CD8α Biotin (Ly-2, BD 
Pharmingen); Streptavidin-Cy3 (BioLegend); anti-mouse CD11c-AlexaFluor® 594 
(N418, BioLegend). 
 
J. Chromatin immunoprecipitation sequencing data analysis 
Original ChIP-Seq data was obtained from NCBI Gene Expression Omnibus 
Database (GEO Accession GSM1309509 and GSM1309511; GSM2259177 and 
GSM2259178) (Iwata et al., 2017; Kurachi et al., 2014). Data were analyzed in 
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Integrative Genomics Viewer (Broad Institute of Massachusetts Institute of 
Technology and Harvard, Cambridge, MA) (Robinson et al., 2011).      
 
K. Retroviral transduction 
pMigR-IRES-EGFP retroviral vectors (Empty vector and IRF4) and pCL-10A1 
packaging vector were co-transfected into Platinum-E retrovirus (RV) packaging 
cells (Cell Biolabs) using TransIT®-293 transfection reagent according to the 
manufacturer’s protocol (Mirus). Isolated spleen OT-I WT and Itk-/- CD8+ T cells 
were stimulated with anti-CD3 (1.0 μg/mL, eBioscience) and anti-CD28 (4.0 
μg/mL, eBioscience) in the presence of IL-2 (20 ng/mL, eBioscience) for 24 h 
before RV transduction. Viral supernatants from RV-transfected cells were 
harvested after 48 h and then transduced to pre-stimulated OT-I T cells in the 
presence of polybrene (8.0 μg/mL) (American Bio) using spin infection for 90 min 
at RT. OT-I CD8+ T cells were re-plated and then stimulated with anti-CD3/CD28 
plus IL-2 for 24 h. Transduced CD8+ T cells were primed in the presence of RA 
and TGF-β for 48 h and then adoptively transferred to congenic WT naïve hosts 
for further analyses.   
 
Materials and Methods for the experiments in Chapter V 
A. Mice 
C57BL/6 WT and congenic Ly5.1 (CD45.1) mice were purchased from Taconic 
Biosciences. All purchased mice were housed and maintained with Itk-/- in our 
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vivarium for several generations before experiments. C57BL/6 Rag1-/- Il2rg-/- mice 
were provided by Michael A. Brehm (UMMS). Mice were housed in SPF 
conditions at the UMMS in accordance with IACUC guidelines. C57BL/6 ILC2-
depleted mice (Il7ra-Cre x Rorafl/fl) were bred and maintained in the animal facility 
of the Kimmel Center for Biology and Medicine of the Skirball Institute at New 
York University School of Medicine in SPF conditions in accordance with the 
animal protocols approved by IACUC of the New York University School of 
Medicine. All uninfected mice were analyzed at 8- to 10-week of age. 
 
B. Antibodies and reagents for flow cytometric analysis 
Cells from the bone marrow, mLN, lung, and small and large intestine were 
stained with anti-mouse CD3 (145-2C11), CD11b (M1/70), CD11c (N418), CD19 
(6D5), CD25 (PC61.5), CD45.1 (A20), CD45.2 (104), CD90.2 (53-2.1), CD127 
(IL-7Rα, A7R34), CD199 (eBioCW-1.2), CD335 (NKp46, PK136), IL-25R (IL-
17RB, MUNC33), integrin α4 (CD49d, 9F10), integrin β7 (FIB504), integrin α4β7 
(LPAM-1, DATK32), KLRG-1 (2F1), ST2 (IL-33R, RMST2-33), NK1.1 (29A1.4), 
Sca-1 (Ly-6A/E, D7), TCRβ (H57-597), TCRγδ (eBioGL3), CXCR4 (L276F12) 
(from eBiosceince, BD Biosciences, BioLegend, and Invitrogen). For intracellular 
staining of transcription factors, the following antibodies were used after fixation 
and permabilization of cells with Fixation/Permeabilzation Concentrate and 
Diluent (eBioscience): GATA-3 (L50-823), RORγt (AFKJS-9), T-bet (4B10) 
(eBioscience). For ICS, cells were stimulated PMA (50 ng/mL) and Ionomycin 
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(1.0 μg/mL) for 5 h at 37￮C in the presence of GolgiStop™ and GolgiPlug™ (BD 
Biosciences). After stimulation, cells were fixed and permeabilized using BD 
Cytofix/Cytoperm Kit (BD Biosciences) to stain intracellular cytokines by anti-
mouse IL-5 (TRFK5) and IL-13 (eBio13A), (eBioscience and BD Biosciences). 
Cells were analyzed on an LSRII flow cytometer (BD Biosciences) and data were 
analyzed with FlowJo (Tree Star).  
 
C. Lineage-depleted bone marrow cell isolation and cell cultures 
Harvested bone marrow cells were counted and lineage-negative cells were 
isolated with Mouse Lineage Cell Depletion Kit (Miltenyi Biotec) according to the 
manufacturer’s protocol. For cell proliferation assays, Lin-depleted bone marrow 
cells were labeled with CellTrace Violet Cell Proliferation Kit (Invitrogen) and 
cultured in the presence of IL-2 (20 ng/mL, Invitrogen) with or without IL-33 (50 
ng/mL, R&D Systems) for 2 d. For gut-homing receptor induction, Lin-depleted 
bone marrow cells were cultured with IL-2 (20 ng/mL), IL-7 (20 ng/mL, 
Invitrogen), IL-33 (20ng/mL) in the presence or absence of RA (1.0 nM, Sigma-
Aldrich) and/or TGF-β (5.0 ng/mL, R&D Systems) for 5 d. For measuring CXCR4 
expression in response to IL-33, Lin-depleted bone marrow cells were cultured 
with IL-2 (10 ng/mL) with or without IL-33 (1 to 10 ng/mL) plus or minus ITK 
inhibitor PRN694 (Zhong et al., 2015) (Principia Biopharma) for 3 d. 
 
D. In vivo injection of IL-33 or IL-2 complexes 
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Mice received daily intraperitoneal injections of PBS or IL-33 (0.3 μg) 7 times in a 
final volume of 200 μL in PBS. For IL-2 complexes, recombinant mouse IL-2 (1.0 
μg) and anti-IL-2 mAb (5.0 μg) (JES6-1A12, Invitrogen) were mixed and 
incubated at 37ºC for 30 min before injection. Incubated IL-2 complex was given 
once per day for 4 days by intraperitoneal injection in a final volume of 200 μL in 
PBS. Lymphocytes from mLN, peritoneal exudates, lung, and small and large 
intestinal lamina propria were isolated for ILC2 analyses. 
 
E. Adoptive transfer of bone marrow ILC2 precursors 
Lineage-depleted BM cells were cultured with IL-2, IL-7, and IL-33 plus RA and 
TGF-β for 3 d and enriched with mouse CD25 MicroBead Kit according to the 
manufacturer’s protocol. CD25-enriched lineage-depleted BM cells (1.0 x 106 
cells) were intravenously injected to naïve Rag1-/- Il2rg-/- mice. Lymphocytes from 
mLN and lamina propria of small and large intestine were isolated at D3 post-
transfer. 
 
F. Dextran sulfate sodium-induced colitis 
For colitis induction, 3.0% of DSS (MW 36,000 to 50,000 Da, Colitis Grade, MP 
Biomedicals) was dissolved in the drinking water and mice were treated for 5 
days and then changed to normal water for 10 days. Weight change was 
monitored daily, and mice were sacrificed at D7 for colon length measurement, 
histological analysis, and isolation of lymphocytes.  
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G. Measurement of intestinal permeability 
Food and water were withdrawn for 6 h and mice were administered FITC–
dextran (MW 4000 Da, Sigma-Aldrich) diluted in sterile PBS at a concentration of 
60 mg/100g body weight by oral gavage. Serum was collected after 4 h of oral 
gavage and FITC-dextran level in the blood was measured with a UV 
spectrophotometer (wavelengths of 490 nm and 520 nm). Serum FITC-dextran 
concentration was determined from standard curves generated by serial dilution. 
 
Statistical analyses 
All statistical analyses were performed using Prism 7 GraphPad Software. 
Differences between individual groups were analyzed for statistical significance 
using Student’s t tests (*, p < 0.05; **, p < 0.01; ***, p < 0.001).  
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As Tec kinase ITK and RLK play a role in TCR-mediated signaling, their impact 
on CD4+ T cell differentiation and effector function was subsequently examined 
by using Itk-/- or Itk-/-Rlk-/- mice. Initial studies showed that ITK is important in TH2 
differentiation in Itk-/- CD4+ T cells in vitro and TH2-biased immunity to N. 
brasiliensis or S. mansoni infection in Itk-/- mice were greatly impaired. In 
contrast, Itk deficiency had little effect on TH1-mediated immunity to intracellular 
protozoan infection (Fowell et al., 1999; Miller et al., 2004). While RLK protein 
expression is undetectable in TH2-polarized CD4+ T cells, RLK is preferentially 
expressed in TH1-polarized CD4+ T cells in vitro (Miller et al., 2004). However, 
functions of ITK and RLK in CD4+ T cells are at least partially redundant, as a 
transgene expression of RLK in Itk-/- mice restores TH2-mediated response in 
allergic asthma and schistosome egg-induced lung granuloma with no notable 
increase in TH1 response (Sahu and August, 2009). Nonetheless, it has been 
difficult to distinguish which phenotypes observed in these mice are due to the 
functions of ITK and/or RLK in mature naïve CD4+ T cells, and which are the 
consequence of altered T cell development generating an abnormal cytokine 
environment in the Itk-/- or Itk-/-Rlk-/- mice. These findings have provided impetus 
for the development of small molecule ITK kinase inhibitors. In this chapter of 
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thesis, I utilized a recently reported small molecule covalent inhibitor of ITK and 
RLK PRN694 (Zhong et al., 2015) and evaluated the effects of ITK/RLK inhibition 
on helper T cell differentiation and effector function in vitro and in vivo.  
 
A. PRN694 potently inhibits CD4+ T helper cell differentiation 
From the molecular structure, PRN694 was predicted to bind covalently to a 
conserved cysteine residue in the ATP binding sites of ITK (C442) and RLK 
(C350), and is highly selective for these two kinases in T cells (Fig. 3.1A). Based 
on in vitro kinase assays, PRN694 is a potent inhibitor of all three Tec kinases 
expressed in T cells, demonstrates less potency toward the other Tec kinases 
BTK and BMX (Fig. 3.1B), and shows high kinome-wide selectivity (Zhong et al., 
2015). Unlike its binding to ITK and RLK, PRN694 does not appear to bind 
covalently to BTK and hence displays a limited duration of BTK inhibition (Zhong 
et al., 2015). Furthermore, PRN694 is 63- to 320-fold more potent in inhibiting 
ITK than previously-described ITK inhibitors, e.g. BMS-509744 and BMS-488516 
(Fig. 3.1B) (Das et al., 2006; Riether et al., 2009; Sahu and August, 2009; Snow 
et al., 2007).  
      To assess the potential effect of PRN694 on CD4+ TH differentiation, I utilized 
naïve CD4+ T cells from B10.A 5C.C7 Rag2-/- TCR Tg mice, and stimulated these 
cells under TH1-, TH2-, or TH17-polarizing conditions. Cells were cultured for 3 
days in the presence of increasing doses of PRN694, and then analyzed for 
cytokine production after restimulation with PMA and Ionomycin for 5 h. Among 
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these conditions, PRN694 inhibited TH1 differentiation more potently than was 
observed for TH2 and TH17 differentiation. Whereas a low concentration of 
PRN694 (25nM) inhibited IFN-γ production by TH1 cells by > 50%, 50-100nM 
PRN694 was required to achieve a similar level of inhibition of IL-17A production 
by TH17 cells (Fig. 3.1C and D). Furthermore, none of the doses tested achieved 
50% inhibition of IL-4 production by TH2 cells. I also examined the expression of 
TH cell lineage-determining transcription factors. Overall, the expression levels of 
all transcription factors tested (T-bet, GATA-3, and RORγt) were decreased upon 
the inhibitor treatment; however, the modest differences observed between the 
three TH cell lineages did not correlate precisely with diminished cytokine 
production (Fig. 3.1E). The effects of PRN694 on cytokine production did not 
correlate with effects on cell proliferation (Fig. 3.2A and B), indicating that the 
inhibition of IFN-γ production by TH1 cells was not due to reduced proliferation of 
these cells in the presence of PRN694. Collectively, these data indicate that 
PRN694 specifically targets ITK and RLK kinase activity and also impairs CD4+ T 
helper cell differentiation and cytokine production, with a range of potency as 
follows: TH1 > TH17 > TH2.  
 
B. PRN694 ameliorates colitis disease progression 
Due to the potent inhibitory effect of PRN694 on IFN-γ production by TH1 cells in 
in vitro culture experiments, I considered whether PRN694 might function in vivo 
to suppress a TH1/ IFN-γ-mediated disease. To test this hypothesis, I adoptively 
 36 
transferred WT colitogenic CD4+ CD45RBhi T cells from C57BL/6 mice into Rag2- 
deficient hosts and monitored the mice for weight loss as an indicator for disease 
progression. Previous studies have demonstrated that the colitis induced in this 
model is due to TH1-mediated inflammation, with little involvement of TH2 or TH17 
effector responses (Neurath et al., 2002; Powrie et al., 1994; Strober and Fuss, 
2011). In addition to the transferred cells, mice received vehicle alone or PRN694 
by oral gavage. Based on studies of ITK target occupancy in thymocytes 
following in vivo administration of PRN694 in mice (Zhong et al., 2015), I dosed 
mice daily (weeks 0-2 and 4-7) and twice daily for a two-week period (weeks 2-4) 
(Fig. 3.3A). As expected, recipient mice receiving vehicle alone failed to gain 
weight and progressively lost weight, beginning 4 weeks after T cell transfer. In 
contrast, PRN694-treated mice exhibited no weight loss and remained similar to 
control Rag2-deficient mice that did not receive a colitogenic T cell transfer (Fig. 
3.3B). Consistent with these data, analysis of colon length at 7 weeks post-
transfer indicated that the reduced colon length seen in the vehicle-treated mice 
was prevented in the PRN694-treated mice (Fig. 3.3C). In addition, histological 
analysis of the colonic epithelium revealed lymphocytic infiltration in the colon of 
the vehicle-treated mice (Fig. 3.3D), in contrast to the reduced inflammation seen 
in the colon of PRN694-treated mice. To further confirm target engagement of 
PRN694 with ITK in vivo, splenic CD4+ T cells were isolated from vehicle-dosed 
or PRN694-dosed mice (2 h or 6 h post-treatment) and then stimulated with anti-
CD3/CD28 mAb to examine PLCγ1 phosphorylation. As shown, the  
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Figure 3.1. PRN694 inhibits CD4+ TH cell differentiation 
(A) Chemical structure of PRN694. (B) The selectivity and potency of PRN694 
was examined by in vitro kinase assay. The table shows the IC50 values for the 
kinases indicated. (C-D) Purified naïve mouse splenic CD4+ T cells were 
stimulated in TH polarizing conditions in the presence o PRN694 at the indicated 
concentrations for 72 h. CD4+ T cells were then re-stimulated with PMA and 
Ionomycin for 5 h and analyzed by intracellular cytokine staining. The untreated 
controls were cultured in the presence of dimethyl sulfoxide (DMSO). The 
percentages of cytokine-producing CD4+ T cells (gated on CD4+ CD44hi) are 
shown (C). Compilation of data from three independent experiments indicating 
the inhibitory effect of PRN694 on the cytokine production are shown. For each 
cytokine, the data were normalized to the percentage of cytokine-producing cells 
in the absence of inhibitor (D). (E) Data from three experiments were compiled, 
and for each TH transcription factor, the data were normalized to the percentage 
of positive cells in the absence of inhibitor.  
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Figure 3.2. PRN694 inhibits CD4+ TH17 proliferation but not TH1 and TH2 
(A-B) CFSE-labeled naïve CD4+ T cells were stimulated with anti-CD3/CD28 
under different TH polarization conditions for 72 h. Histograms are shown to 
analyze the magnitude of CD4+ T cell proliferation. Mean fluorescence intensity of 
CFSE (Top, left) and percentages of more-divided (diluted) CD4+ T cells (Bottom, 
left) are shown (A). Calculated CD4+ T cell numbers of each cell division (Cell 
divisions #1-5) by FlowJo software are shown. Data from three experiments were 
compiled (B).  
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phosphorylation of PLCγ1 was completely blocked at both time points following 
PRN694 administration (Fig. 3.3E). Together, these data demonstrate that 
PRN694 reduces T cell-mediated colonic inflammation by inhibiting ITK/RLK. 
 
C. PRN694 impairs colitogenic TH1 response and also prevents CD4+ T cell 
migration to the colon 
To determine the basis of PRN694-mediated inhibition of colitis, I analyzed the T 
cell populations in the spleen, mesenteric lymph node, intestinal epithelium, and 
lamina propria of recipient Rag2-/- mice at 7 weeks post-transfer. Assessment of 
CD4+ T cell proportions did not reveal any significant differences in the spleens or 
mLNs between the vehicle- or PRN694-treated mice, although a modest but 
significant difference in absolute numbers of CD4+ T cells was observed in mLN 
(Fig. 3.4A and B). However, CD4+ T cell proportions in intestinal epithelium and 
LP of PRN694-treated mice were significantly less than those seen in the 
vehicle-treated mice, along with a statistically significant difference in absolute 
numbers in the LP (Fig. 3.4A and B). To test whether PRN694 exerted any 
inhibitory effect on T cell function, I examined cytokine production from 
transferred colitogenic T cells in several different organs after a brief in vitro 
stimulation. As expected, CD4+ T cells showed robust IFN-γ production in all 
analyzed sites of vehicle-treated mice, whereas no IL-17A production was 
observed (Fig. 3.4C). Interestingly, PRN694 administration markedly reduced the  
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Figure 3.3. PRN694 administration ameliorates colitis disease progression and 
inhibits PLCγ1 phosphorylation in vivo  
(A-D) Colitogenic CD4+ CD45RBhi splenic T cells (4.0 x 105 cells/mouse) from B6 
WT mice were injected IP into B6 Rag2-/- hosts. Recipients were treated with 
vehicle (red, n=5) or PRN694 (blue, n=5) with the indicated regimen (A), and 
disease progression of dosed recipients and untreated (No CD4+ CD45RBhi T cell 
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transfer) Rag2-/- controls (Black, n=4) was monitored by weight change (B). Data 
are shown as mean ± SEM. At 7 weeks post-transfer, untreated Rag2-/- control, 
vehicle-dosed, and PRN694-dosed mice were sacrificed for the measurement of 
colon length (C) and histologic analysis using H&E staining (10X and 40X) (D). 
Data are compiled from two independent experiments. (E) Splenic CD4+ T cells 
isolated from vehicle-dosed (n=2) or PRN694-dosed (40 mg/kg) (2 h post-
treatment, n=3; 6 h post-treatment, n=3) mice were stimulated with anti-
CD3/CD28 for 5 min and then lysed to examine the phosphorylation of PLCγ1 
(Tyr783) by western blot. Both p-PLCγ1 (Top) and total PLCγ1 (Bottom) are 
shown. 
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proportions of CD4+ T cells producing IFN-γ in mesenteric LN, IEL and LP, 
although this effect was less prominent in the spleen (Fig. 3.4C and D). There  
was also a large decrease in the numbers of IFN-γ-producing CD4+ T cells in all 
organs following PRN694 treatment, although the suppression did not reach 
significance in the LP (Fig. 3.4E). Consistent with in vitro studies, the reduced 
production of IFN-γ by T cells in the PRN694-treated mice could not be 
accounted for simply by defects in expression of the TH1 transcription factor, T-
bet (Fig. 3.5A and B). 
      Due to the reduced proportion of CD4+ T cells in the inflamed intestines of 
PRN694-treated mice, I also investigated expression of gut-homing receptors, 
integrin a4b7 (LPAM-1) and CCR6, on colitogenic T cells (Monteiro et al., 2011; 
Petrovic et al., 2004; Varona et al., 2005). Consistent with the proportions of gut-
infiltrating CD4+ T cells, expression of both integrin a4b7 and CCR6 were 
reduced on intestinal epithelial CD4+ T cells when PRN694 was administered 
(Fig. 3.5C and D). In contrast, I did not detect any significant level of expression 
of these receptors on LP-isolated CD4+ T cells from either group of mice (Fig. 
3.5C and D). Together, these data suggest that PRN694 attenuates in vivo TH1-
biased intestinal inflammation through the inhibition of IFN-γ production and the 
expression of intestine-homing surface receptors.  
 
D. PRN694 decreases Treg differentiation and IL-2 production from CD4+ T 
cells 
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Figure 3.4. PRN694 treatment reduces colitogenic CD4+ T cell migration to the 
colon and inhibits IFN-γ production 
(A-B) The proportions and absolute numbers of CD4+ T cells in spleen, 
mesenteric lymph nodes, intestinal epithelium, and colon lamina propria are 
shown. (C-E) Isolated lymphocytes from various sites were stimulated with PMA 
and Ionomycin, and analyzed for IL-17A and IFN-γ production. Dot plots show 
gated CD4+ CD44hi T cells (C). The proportions (D) and numbers (E) of IFN-γ-
producing CD4+ T cells are shown. Data are compiled from two independent 
experiments. 
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Figure 3.5. PRN694 treatment inhibits T-bet expression and reduces gut-homing 
receptor expression in intraepithelial CD4+ T cells 
(A-B) Isolated CD4+ T cells from each different organ of vehicle-treated or 
PRN694-treated mice at 7 weeks of post-transfer were analyzed for T-bet 
expression, and the percentages of T-bet+ CD4+ T cells are shown (A). Graph on 
the right shows a compilation of data from 3-5 mice in each group (B). (C-D) 
Histograms show the expression of gut-homing receptors, integrin a4b7 (LPAM-
1) and CCR6, on colonic IEL and LP CD4+ CD44hi T cells. Numbers indicate the 
percentages of cells in each region (C). Graph shows a compilation of data from 
3-5 mice in each group (D). 
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A recent study has shown that Itk-/- CD4+ T cells have an increased propensity to 
upregulate Foxp3 and differentiate into iTreg cells when stimulated under TH17-
polarizing conditions (Gomez-Rodriguez et al., 2014). I therefore considered 
whether the inhibitory effect of PRN694 on colitis might be due to enhanced 
differentiation of Foxp3+ iTreg cells in the inhibitor-treated mice. Instead, analysis 
of T cells at 7-weeks post-transfer indicated that PRN694 significantly reduced 
the proportions of CD4+ T cells expressing Foxp3 compared to controls, a result 
consistent with the findings of Huang et al. (W. Huang et al., 2014). This was 
evident in all organs examined (Fig. 3.6A and B). Examination of surface markers 
commonly found on the majority of Treg cells, including CTLA-4, PD-1, and 
GITR, also showed reduced expression on Foxp3+ CD4+ T cells in PRN694-
treated mice (Fig. 3.6C-H).  
      Since upregulation of Foxp3 and iTreg differentiation are dependent on IL-2, I 
examined the effects of PRN694 on IL-2 production by in vitro polarized CD4+ T 
cells. As shown, PRN694 inhibited IL-2 production by all three lineages of T 
helper cells (Fig. 3.7A and B). Consistent with these data, T cells from the 
adoptive transfer colitis studies also showed reduced proportions of cells capable 
of producing IL-2 following treatment with PRN694 (Fig. 3.7C and D). These data 
indicate that reduced disease progression in mice treated with PRN694 is not a 
consequence of enhanced differentiation of Foxp3+ iTreg cells, but rather a result 
of inhibition of differentiation and activation of the IFN-γ-producing TH1 effector 
cell population. 
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Figure 3.6. PRN694 treatment reduces Treg frequencies in vivo and inhibits Treg 
surface marker expressions  
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(A-B) CD4+ T cells from spleen, mLN, IEL, and lamina propria from vehicle-
treated or PRN694-treated mice at 7 weeks of post-transfer were examined for 
Foxp3 expression. (A) Dot plots show CD4 vs. Foxp3 staining, with numbers 
indicating the percentages of CD4+ Foxp3+ Treg cells, and (B) the graph shows a 
compilation of data from 3-5 mice in each group. (C-H) Histograms show the 
expression of CTLA-4 (C), PD-1 (D), and GITR (E) on CD4+ Foxp3+ Treg cells 
isolated from spleen, mesenteric LN, intestinal epithelium (IEL), and lamina 
propria tissue (LPL) of vehicle-treated (-) or PRN694-treated (+) mice. Graphs 
shown each panel represent the compiled data from 3-5 mice in each group. 
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Figure 3.7. PRN694 treatment decreases IL-2 production from CD4+ T cells in 
vitro and in vivo  
(C-D) Naïve CD4+ T cells were stimulated in TH polarizing conditions with 
PRN694 at the indicated concentrations for 72 h. Cells were then re-stimulated 
with PMA and Ionomycin for 5 h and then analyzed for IL-2 production. (C) The 
percentages of IL-2-producing CD4+ T cells (gated on CD4+ CD44hi) are shown. 
(D) Compilation of data from 3 independent experiments is shown, with the data 
for each TH subset normalized to the percentage of positive cells in the absence 
of inhibitor.   
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
32.1
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
23.5
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
14.1
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
11.1
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
25.2
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
68.9
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
30.1
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
31
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
52.6
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
10.9
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
56.3
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
10.9
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
17.5
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A>
: C
D
44
30.4
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<A
m
C
ya
n-
A
>:
 C
D
44
21.6
IL-2
Untreated 200nM100nM50nM25nM
PRN694
TH1
TH2
TH17
C
D
4
32.1 23.5 25.2 14. 11.
68 9 52 6 31.0 30 1 10.9
56.3 10.9 17. 30.4 21.6
(Gated on CD4+ CD44hi T cells)
0 50 100 150 200
0
25
50
75
100
Inhibitor Conc. (nM)
%
 o
f C
on
tr
ol
IL-2 Production 
(CD4+ T cells)
IL-2
C
D
4
TH1
TH2
TH17
Control 2 5 75 1 M
PRN694
10
75
%
 o
f C
on
tro
l
IL-2 Production
(In vitro)
0 50 100 150 200
0
25
50
75
100
Inhibitor Conc. (nM)
%
 o
f C
on
to
l
** **
*** ***
TH1 (IFN-γ+)
TH2 (IL-4+)
TH17 (IL-17A+)
CD4+ TH Differentiation
%
 o
f C
on
tr
ol
Inhibitor Conc. (nM) 
*
0 50 100 150 200
0
25
50
75
100
Inhibitor Conc. (nM)
%
 o
f C
on
to
l
0 50 100 150 200
Inhibitor (nM)
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4 16.2
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4 3.69
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4 12.9
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4 6.24
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4 8.12
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4 3.62
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4
5.83
0 103 104 105
0
102
103
104
105
<APC-A>: IL-2
<P
er
C
P-
C
y5
-5
-A
>:
 C
D
4
0.799
12.9 16.2 8.
3.6
5.
0.8
3.76.2
Spleen Mesenteric LN IEL Lamina Propria
PRN
694
Vehicle
C
D
4
IL-2
(Gated on CD4+ CD44hi T cells)
IL-2 Production
0
5
10
15
20
Pe
rc
en
ta
ge
 (%
)
**
*
*
*
- + - + - + - +
Spleen mLN IEL LP
S l mLN I LPL
C
D
4
IL-2
Vehicle
PRN694
5
2
10
7
LPL
IL-2 Production
(In vivo)
A B
C D
 50 
E. PRN694 leads to impaired P-selectin binding and chemokine-induced 
CD4+ T cell migration 
The results in the adoptive transfer colitis studies showed reduced numbers of 
CD4+ T cells present in the colonic epithelium of PRN694-treated mice compared 
to controls. As previous studies using naïve T cells from Itk-/- and Itk-/-Rlk-/- mice 
had shown a role for these kinases in CCL19- and CXCL12-induced migration 
(Fischer et al., 2004; Takesono et al., 2004), I considered whether CD4+ effector 
T cells might also require ITK and RLK for efficient migration into tissues. Using 
CD4+ T cells polarized in vitro to TH1, TH2, or TH17 lineages in the presence or 
absence of PRN694, I first examined binding to P-selectin, a ligand expressed on 
activated endothelium (Ley and Kansas, 2004). Both TH1 and TH17 cells showed 
reduced P-selectin binding following differentiation in the presence of both doses 
of PRN694 tested; in contrast, TH2 cells showed only a modest reduction, and 
this reduction was only visible in the higher dose of inhibitor (Fig. 3.8A and B). 
      As a second approach, I tested migration of CD4+ effector T cells to 
chemokines implicated in trafficking to the gastrointestinal epithelium. I focused 
on responses to CXCL11, a ligand for CXCR3 commonly found on effector TH1 
cells (Qin et al., 1998), CCL20, a ligand for CCR6 found on TH17 cells 
(Esplugues et al., 2011; Wang et al., 2009), and CCL25, a ligand for CCR9 
(Cassani et al., 2011; Stenstad et al., 2006), which is expressed on gut-resident 
T cells. Using Transwell migration assay, I found that PRN694 inhibited TH1 
migration to CXCL11, with little migration observed by other subsets to this 
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chemokine (Fig. 3.8C). CCL20 induced a modest degree of migration of TH17 
cells, and this migration was reduced approximately two-fold by PRN694. TH0 
and TH1 cells showed fewer cells migrating in response to CCL20, and these 
responses were further reduced by PRN694 (Fig. 3.8D). Overall, few cells of any 
lineage migrated in response to CCL25, with significant inhibition seen only in 
TH1 and TH0 cells (Fig. 3.8E). Overall, these data confirm that PRN694 impacts 
differentiating TH1 and TH17 cells to reduce their ability to bind to activated 
endothelium and to migrate in response to inflammatory chemokines. 
 
F. Discussion to Chapter III 
In this chapter, I show that inhibition of ITK and RLK by PRN694 leads to a 
significant impairment in CD4+ TH cell differentiation and to protection from TH1-
mediated colitis. Although PRN694 treatment inhibited the differentiation of all 
CD4+ TH subsets in vitro, the most potent inhibitory effect I observed was on TH1 
differentiation. These findings are consistent with a recent study using an allele-
sensitive mutant of ITK coupled with a selective inhibitor, which also revealed an 
important role for ITK kinase activity in TH1 differentiation and cytokine production 
(Kannan et al., 2015a). The data with PRN694 are also consistent with previous 
studies showing that Itk-/- Rlk-/- mice mounted a normal protective type II cytokine 
response against S. mansoni, but were highly susceptible to the intracellular 
protozoan, Toxoplasma gondii (Schaeffer et al., 2001; 1999) . Furthermore, these 
results strongly suggest that a dual inhibitor of ITK and RLK would likely have a  
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Figure 3.8. PRN694 treatment impairs P-selectin binding and inhibits 
chemokine-induced CD4+ T cell migration 
(A-E) Isolated naïve CD4+ T cells were cultured in the presence or absence of 
PRN694 (25 or 50nM) for 72 h in each TH polarization condition. (A) Histograms 
show polarized CD4+ T cells stained with recombinant P-selectin-human IgG 
fusion protein as an assay for PSGL-1 binding. Numbers (blue) at the right 
indicate the percentages of cells staining positively for P-selectin-Ig based on 
comparison to an isotype control stain; numbers at the left of each histogram 
indicate the mean fluorescence intensity (MFI) of P-selectin-Ig staining in each 
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panel. (B) Graph shows a compilation of data from two independent experiments 
The data were normalized to the percentage of P-selectin binding cells among 
each TH polarizing condition in the absence of inhibitor. (C-E) Cultured CD4+ T 
cells (5.0 x 105 cells) were plated in the upper chamber of a HTS Transwell-96 
well permeable supports (3.0 μm pore); bottom chambers were loaded with 
diluted CXCL11 (100 ng/mL) (C), CCL20 (100 ng/mL) (D), or CCL25 (300 ng/mL) 
(E). After 3 h at 37°C, the numbers of migrated cells were counted by the flow 
cytometer. The chemotaxis index was calculated by dividing the number of cells 
that migrated in response to each chemokine by the number of spontaneously 
migrated cells.  
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different effect on TH2-skewed inflammation such as asthma or atopic diseases 
compared to an inhibitor that was selective for ITK alone. 
      Also consistent with previous studies using Itk-/- T cells (Gomez-Rodriguez et 
al., 2009), I observed that PRN694 was a potent inhibitor of TH17 differentiation 
and IL-17A production in vitro. Nonetheless, it is unlikely that inhibition of TH17 
responses can account for the effects of PRN694 in ameliorating disease in the 
colitis experiments. While some studies have shown a role for TH17 cells in colitis 
(Elson et al., 2007; Noguchi et al., 2007; O'Connor et al., 2009), these effects 
were seen either when colitogenic BALB/c T cells were transferred to syngeneic 
hosts (Noguchi et al., 2007) or when the cecal bacterial antigen-specific 
C3H/HeJBir CD4+ T cell lines were transferred to C3H.SCID hosts and then 
restimulated for 10 days in the presence of bacterial antigen-pulsed DCs and 
with or without IL-23 prior to analysis (Elson et al., 2007). In contrast, a study 
using a protocol most similar to this experiment found that colitis was actually 
enhanced when TH17 responses were eliminated (O'Connor et al., 2009), and 
the transfer of naïve CD4+ T cells from Il17a-/- mice still induced a severe colitis 
(Noguchi et al., 2007). Furthermore, several other reports suggest that TH17 
responses arise early on during colitis disease progression and that in vitro 
polarized TH17 cells are eventually converted into TH1 cells after adoptive 
transfer to lymphopenic hosts (Feng et al., 2011; Harbour et al., 2015). Using this 
CD4+ CD45RBhi adoptive transfer model of T cell-mediated colitis, I was unable to 
detect IL-17A production from colitogenic T cells in mice that were treated with 
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vehicle alone, suggesting that TH17 responses were not contributing to disease 
progression in this study. Thus, I was unable to assess the efficacy of PRN694 to 
inhibit IL-17A production in vivo in this disease model. 
      In this study, I cannot rule out an effect of PRN694 on the Tec kinase family 
member, Tec. Previous studies have indicated that Tec mRNA expression is 
negligible in primary T cells examined ex vivo, including memory phenotype cells 
(Felices et al., 2009) (www.immgen.org) and that only modest increases in Tec 
protein expression (< 2-fold) are observed even after TH1 polarization in vitro 
(Tomlinson et al., 2004). Furthermore, studies of T cell responses in Tec-/- mice 
have failed to reveal any significant defects due to the absence of Tec. 
Therefore, it seems unlikely that the inhibitory effects of PRN694 observed in this 
study are due to its effect on Tec activity in T cells. 
      Interestingly, I observed reduced differentiation of Foxp3+ iTreg cells in 
PRN694-treated mice compared to controls. This is in contrast to a previous 
study showing increased differentiation Itk-/- naïve CD4+ cells into of Foxp3+ iTreg 
cells in a similar adoptive transfer model of colitis (Gomez-Rodriguez et al., 
2014). The difference in these two sets of findings could be due to a number of 
factors. First, the numbers of cells transferred and the time points analyzed were 
each different in the two studies. More importantly, there may be an 
unappreciated difference in the starting populations of CD4+ CD45RBhi CD25- T 
cells isolated from WT mice, as in this current study, compared to those isolated 
from Itk-/- mice. In addition, PRN694 is a potent inhibitor of both ITK and RLK, 
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and this dual inhibition may lead to a different outcome than the single genetic 
deficiency in Itk. It is also important to consider that a small molecule kinase 
inhibitor might have a different effect than a genetic deficiency that causes a 
complete absence of ITK protein, as the former situation would not abolish any 
kinase-independent functions of ITK. Finally, it is important to consider the 
possibility that mice housed in two different environments have significant 
differences in their microbiota, and that these differences may impact iTreg 
differentiation in vivo. 
      This study reveals that PRN694 treatment reduces the numbers of 
colitogenic CD4+ T cells in the intestinal epithelium at 7 weeks post-transfer. It is 
possible that one component of this decrease is reduced proliferation of the T 
cells in the presence of PRN694, although in vitro studies examining proliferation 
suggest that this explanation is unlikely. Instead, I propose that impaired T cell 
migration to the gastrointestinal tract is contributing to this deficit. I find that 
PRN694 treatment during T helper cell polarization leads to reduced P-selectin 
binding on TH1 and TH17 cells, an alteration that could impact T cell rolling on the 
activated endothelium prior to extravasation into the GI tract. This possibility is 
consistent with previous studies showing impaired tissue homing and 
transendothelial migration of Itk-/- T cells in an autoimmune disease model (Jain 
et al., 2013). Furthermore, I observed reduced expression of integrin a4b7 and 
CCR6, and reduced in vitro chemotaxis to inflammatory chemokines, by 
PRN694-treated CD4+ T cells. Together, these data provide strong support for 
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the conclusion that ITK/RLK inhibition leads to impaired T cell migration into the 
GI tissue.  
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CHAPTER IV: THE TEC KINASE ITK IS REQUIRED FOR ANTI-
VIRAL IMMUNITY TO GAMMAHERPESVIRUS INFECTION AND 
T CELL MIGRATION TO THE INTESTINE 
 
The Tec family kinase ITK functions in T cell activation to regulate gene 
expression following TCR stimulation. In the absence of ITK, TCR-mediated 
downstream signaling are greatly impaired, but not completely abolished 
(Andreotti et al., 2010; Berg et al., 2005; Schwartzberg et al., 2005; Wilcox and 
Berg, 2003). ITK regulates the differentiation of naïve CD4+ T cells into various 
TH cell lineages, and is required for effector T cell responses that protect against 
various pathogen infections and that contribute to allergic and autoimmune 
responses (Fowell et al., 1999; Gomez-Rodriguez et al., 2009; Jain et al., 2013; 
Miller et al., 2004; C. Mueller and August, 2003). Itk-/- mice generate protective 
immune responses to a range of viral infections (Atherly et al., 2006b; Bachmann 
et al., 1997), while in humans, the mutations in ITK leads to fatal EBV-induced 
lymphoproliferative disease (Ghosh et al., 2014; Huck et al., 2009; Linka et al., 
2012; Mansouri et al., 2012; Stepensky et al., 2011). To date, the function of ITK 
in protective immunity to persistent virus infections has not been examined. In 
this chapter, I examined the function of ITK in anti-viral immunity to 
gammaherpesvirus infection in mice by using MHV68, and also investigated an 
underlying molecular mechanism of how ITK regulates the migration of T cells to 
the intestine in a steady-state. 
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A. Itk-/- mice control MHV68 replication in the spleen 
To investigate the ability of mice with a germline mutation in Itk to mount a 
protective immune response to gammaherpesvirus infection, I infected WT and 
Itk-/- mice with 1.0 x 106 PFU of MHV68 via intraperitoneal injection and examined 
the CD8+ T cell response at acute and latent phase time points (Fig. 4.1A). I 
observed a reduced frequency of MHV68-specific CD8+ T cells in the spleens of 
Itk-/- mice compared to controls at both day 7 (D7) and D14 of post-infection. 
Upon ex vivo stimulation with the immunodominant epitope ORF75c (Gredmark-
Russ et al., 2008), a smaller percentage of Itk-/- CD8+ T cells produced IFN-γ and 
in addition, the frequencies of ORF75c-specific CD8+ T cells were reduced in Itk-/- 
compared to WT infected mice, a difference that persisted to D60 of post-
infection (Fig. 4.1B-D). MHV68 viral DNA copy numbers in the spleens were 
higher in infected Itk-/- mice than in WT mice at D7 post-infection, but by D14 and 
later, no further differences in splenic viral DNA copy number were observed 
(Fig. 4-1E). This modestly impaired anti-viral immune response by Itk-/- mice is 
consistent with previous studies of other acute virus infections (Atherly et al., 
2006b; Bachmann et al., 1997). Despite the reduced magnitude of the anti-viral 
CD8+ T cell response, Itk-/- mice ultimately cleared each of these acute viral 
infections, and showed no defect in the control of acute MHV68 infection in the 
spleen. 
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Figure 4.1. Itk-/- mice control MHV68 infection in the spleen 
(A) Scheme of MHV68 infection (IP) of WT and Itk-/- mice. (B) Isolated 
splenocytes at D7 and D14 post-infection were stimulated with the MHV68 
ORF75c peptide for 5 h, and stained for intracellular IFN-γ. Data are 
representative of 2-4 experiments per timepoint. Numbers on dot-plots indicate 
mean ± SEM of IFN-γ producing cells. (C-D) The frequencies (C) and absolute 
numbers (D) of MHV68-specific CD8+ splenocytes were determined by tetramer 
staining. (E) Viral copy number of MHV68 DNA in the spleen from 3-4 
experiments per timepoint.  
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B. Itk-/- mice fail to control MHV68 replication in the intestine and exhibit gut 
pathology during viral latency 
Additional cohorts of WT and Itk-/- mice were infected with MHV68 as above and 
were assessed for their ability to control latent MHV68. In contrast to WT mice, 
which remained healthy throughout the time course of these studies, Itk-/- mice 
showed signs of gastrointestinal distress and began to succumb to the infection 
after long-term latency (> D100 post-infection) (Fig. 4.2A). The impaired survival 
of latently-infected Itk-/- mice was accompanied by high viral loads in small 
intestine at D180 of post-infection (Fig. 4.2B). These findings prompted us to 
examine viral DNA copy numbers in the intestine at early timepoints post-
infection (D7 and 14), revealing that viral DNA copy numbers were significantly 
higher in the small intestines of Itk-/- mice compared to WT controls (Fig. 4.2C). 
      I also tested whether latently-infected Itk-/- mice displayed exacerbated 
pathology following viral reactivation induced by TLR agonists, such as LPS or 
CpG DNA (Gargano et al., 2009). WT and Itk-/- mice were infected with MHV68, 
and then treated with a single intraperitoneal injection of a subclinical dose of 
LPS (20 μg/mouse) at varying time points post-infection (D30, 60, D90, and 
D100) (Fig. 4.3A). Interestingly, Itk-/- mice harboring latent MHV68 and treated 
with LPS exhibited severe gut inflammation; furthermore, the severity of the 
inflammation increased as the latency period increased, such that the majority 
(11 out of 18, 61.1%) of Itk-/- mice given LPS at D90-100 post-infection 
succumbed within 1-2 days of treatment (Fig. 4.3B). In contrast, WT latently- 
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Figure 4.2. Itk-/- mice fail to control MHV68 infection in the intestine    
(A) Survival of WT (n=24) and Itk-/- (n=24) mice after MHV68 infection. No 
difference in survival of uninfected WT and Itk-/- mice was observed (not shown). 
(B-C) Compilation of viral DNA copy numbers in sections of small and large 
intestine (Duo, Duodenum; Jej, Jejunum; Ile, Ileum; Col, Colon) at D180 (B) and 
D7 and D14 (C) post-infection.
A B
C
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infected mice given LPS, naïve WT mice, and naïve Itk-/- mice were all devoid of 
detectable gut pathology and severe inflammation (Fig. 4.3C-E). A similar finding 
was also observed in Itk-/- mice given their primary MHV68 infection by the 
intranasal route (1.0 x 103 PFU/mouse). When these latently-infected mice were 
treated with a single IP injection of LPS at D60 post-infection, severe gut 
pathology was observed (Fig. 4.3F). Examination of the lungs in these mice 
showed only a modest level of inflammation, and no obvious differences between 
WT and Itk-/- responses (Fig. 4.3G). These results suggest that ITK is required for 
the control of latent MHV68 infection in the intestine.  
 
C. Anti-viral CD8+ T cells require ITK for accumulation in the intestine 
In light of the intestinal pathology observed in MHV68-infected Itk-/- infected 
hosts, I considered whether these mice had a defect in generating anti-viral CD8+ 
T cell responses in the intestine. I assessed MHV68-specific CD8+ T cells in the 
spleen, mesenteric lymph node, intraepithelial lymphocytes (IEL), and lamina 
propria lymphocytes (LPL) from both small intestine (si) and colon (c) tissue 
(siIEL, cIEL, siLPL, and cLPL) at D7 post-infection in WT and Itk-/- mice. 
Surprisingly, Itk-/- mice had significantly reduced numbers of total CD8+ T cells in 
the mLN, IELs, and LPLs, and consequently, had very few virus-specific cells in 
these compartments (Fig. 4.4A). Although the numbers of total splenic CD8+ T 
cells in infected WT versus Itk-/- mice were comparable, fewer CD8+ T cells were 
found in the intestines of Itk-/- mice (Fig. 4.4B); furthermore, both tetramer-positive  
 65 
 
Figure 4.3. LPS administration induces a lethal gastrointestinal inflammation in 
MHV68-infected Itk-/- mice during latency but not in the lung 
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A single sub-clinical dose of LPS (20.0 μg/mouse) was injected IP into MHV68-
infected (infection by IP route) WT and Itk-/- hosts at varying timepoints (D30 to 
D100) during latency. (B) Percentage survival of WT and Itk-/- infected mice after 
LPS injection at D30 (n=12), D60 (n=10), D90 (n=10), and D100 (n=8 to 10). (C-
E) Histologic analyses of duodenum from LPS-treated (D1 post-LPS) MHV68-
infected mice at D100 post-infection (C), uninfected naïve (D), and LPS-treated 
uninfected at D3 post-LPS (E) WT and Itk-/- mice. Images shown images are at 
10X magnification. Bar, 75 μm. (F) WT and Itk-/- mice were infected with MHV68 
(IP or IN) for 60 days, and then analyzed 3 days after LPS injection. Histology of 
duodenum is shown; images are at 10X magnification. Bars, 75 μm. (G) 
Histology of lungs from MHV68-infected mice at D60 after D3 of post-LPS 
injection (IP). Shown images are at 10X magnification. Bar, 75 μm. Data are 
representative of 4 mice of each genotype. 
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CD8+ T cell proportions and absolute numbers were significantly reduced in all 
tissues of Itk-/- mice, with the largest difference seen in siLPL (Fig. 4.4A and C).  
 
D. Impaired anti-viral CD8+ T cell migration to the intestine is a cell-intrinsic 
defect in the absence of ITK 
To determine if the defect in Itk-/- CD8+ T cell numbers in the intestine is a feature 
intrinsic to a lack of ITK in these cells, or to defects caused by altered 
environmental factors in Itk-/- mice, I performed adoptive transfer experiments. 
Recipient mice received congenically marked WT (CD45.2) or Itk-/- (CD45.1) OT-I 
TCR transgenic (Rag2-/- or Rag1-/-) CD8+ T cells (5.0 x 105) followed by infection 
with an MHV68 strain expressing OVA (MHV68-M3-OVA). Despite the reduced 
percentages of MHV68-specific CD8+ T cells in the spleens of MHV68-infected 
intact Itk-/- compared to WT mice, no such difference was observed for WT versus 
Itk-/- OT-I T cells in the spleens of adoptive transfer recipients after infection. In 
contrast, the frequency of Itk-/- OT-I T cells in the small intestinal epithelium and 
lamina propria were significantly reduced compared to WT OT-I cells (Fig. 4.5A 
and B). The Itk-deficient OT-I T cells in these tissues also had smaller 
percentages expressing CD69 and CD103 compared to WT OT-I cells (Fig. 4.5C 
and D), consistent with a potential defect in Itk-/- CD8+ T cell migration and/or 
tissue retention in the intestine. Taken together, these data suggest that ITK is 
required in CD8+ T cells for efficient homing and/or retention of these cells in the 
intestinal tissue in response to virus. 
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Figure 4.4. Effector CD8+ T cell numbers in the intestinal tissue of MHV68-
infected mice are reduced in the absence of ITK 
(A) MHV68-specific CD8+ T cells in various organs at D7 post-infection were 
identified by tetramer staining. Data are representative of 3 experiments (mLN, 
mesenteric lymph node; siIEL, small intestine intraepithelial lymphocytes; cIEL, 
colon intraepithelial lymphocytes; siLPL, small intestine lamina propria 
lymphocytes; cLPL, colon lamina propria lymphocytes. (B-C) Compilations of 
absolute numbers of total (B) and MHV68-specific (C) CD8+ T cells in various 
organs at D7 post-infection.  
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Figure 4.5. Impaired gut-homing of Itk-/- CD8+ T cells is cell-intrinsic to ITK 
deficiency 
Congenically-labelled OT-I WT (CD45.2, blue box) or Itk-/- (CD45.1, red box) 
CD8+ T cells (5.0 x 105 cells) were transferred into WT recipients. Recipient mice 
were infected with MHV68-M3-OVA and OT-I cells were analyzed at D7 post-
infection (A). Compilation of data from 4-6 infected recipients per group is shown 
(B). (C-D) OT-I cells shown in (A) from small intestine were analyzed for CD69 
A
C
B
D
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and CD103 expression (C). Compilation of percentages of CD69+ CD103+ OT-I T 
cells from flow cytometric data is shown (D). 
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E. Itk-/- mice have a steady-state reduction in gut-resident T cell numbers 
As MHV68-infected Itk-/- mice suffered from gastrointestinal pathology and low 
anti-viral CD8+ T cell numbers in the tissue after MHV68 infection, I considered 
whether these mice might have a steady-state reduction in gut-resident T cell 
numbers. Confocal imaging of WT small intestines (duodenum) showed the 
expected localization of CD8+ T cells in the intestinal epithelium (IEL) and lamina 
propria (LPL) of uninfected mice (Fig. 4.6A and B). Strikingly, uninfected Itk-/- 
mice had noticeably fewer CD8+ T cells in both the lamina propria and 
intraepithelial compartments (Fig. 4.6A and B). These findings were confirmed by 
flow cytometry of dissociated tissues. Consistent with the enhanced gut 
pathology and reduced lymphocyte cellularity in the intestine following MHV68 
infection, T cell numbers in both cellular compartments of Itk-/- mice were 
significantly reduced compared to WT uninfected mice (Fig. 4.6C and D). To 
determine whether there was any alteration in the T cell subsets found in the 
intestinal compartments of WT versus Itk-/- mice, I examine IELs in the small 
intestine for CD8αα, CD8αβ, CD4+ CD8αβ-, and CD4- CD8αβ- subsets of TCRβ+ 
or TCRγδ+ cells (Fig. 4.7A-D). This analysis revealed no profound differences in 
specific IEL subpopulations in Itk-/- mice, and instead, confirmed a global 
reduction in intestinal T cell numbers in the absence of ITK (Fig. 4.7A-D). Overall, 
these data are consistent with a role for ITK in intestinal T cell migration and/or 
retention, both under steady-state conditions and in response to virus infection.  
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Figure 4.6. Itk-/- mice have a steady-state reduction in gut-resident T cells 
(A-B) Confocal microscopy of intestinal tissue (Duodenum) from uninfected WT 
and Itk-/- mice. Staining with DAPI (blue), anti-CD11c (yellow), anti-CD8 (red), and 
merged images are shown. All images are at 20X magnification and tiled (3X3) 
by Carl Zeiss ZEN lite software (A). White squares indicated in the merged 
images in (A) were magnified by 4.0X (B). Bar, 100 μm. (C-D) Compilation data 
of CD4+ (C) and CD8+ (D) T cell numbers in the intestinal tissue are shown.   
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Figure 4.7. Similar subset composition of gut-resident TCRβ+ and TCRγδ+ IELs 
in the small intestines of WT and Itk-/- mice  
(A-D) Flow cytometic analysis of intraepithelial lymphocytes from the small 
intestines (siIEL) of naïve WT and Itk-/- mice. Cells shown are gated on 
lymphocytes (top row, left) (A). Gated TCRβ+ (blue box from A) or TCRγδ+ (red 
box from A) cells were examined for CD8α versus CD8β staining (top row, right) 
(B). Gated TCRβ+ CD8α- CD8β- cells (yellow box from B) were examined for CD4 
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expression (bottom row, right) (C). Compilation of data from 4-7 mice per 
genotype indicate the relative proportions of each subset (bottom row, left) (D).    
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F. Impaired expression of gut-homing receptors on CD8+ T cells in 
uninfected Itk-/- mice 
Examination of adoptively-transferred OT-I WT or Itk-/- CD8+ T cells in MHV68-
infected recipients indicated that anti-viral T cells lacking ITK had a defect in 
expressing homing receptors known to be important in migration and tissue 
retention in the intestine (Fig. 4.5C and D). To determine whether a similar defect 
was present at steady-state in uninfected Itk-/- mice, I examined CD69, CD103, 
integrin α4β7, and CCR9 on CD8+ T cells isolated from the gut and the mLN of 
WT and Itk-/- mice. From the few CD8+ T cells that were recovered from all 
compartments of the intestinal tissue in Itk-/- mice, a smaller proportion of Itk-/- IEL 
cells co-expressed CD69 and CD103 compared to WT IEL. These data were 
consistent with a substantial reduction in the proportion of Itk-/- CD8+ T cells 
expressing CD103 in the mLN (Fig. 4.8A and B). Examination of integrin α4β7 
and CCR9 expression also revealed a significant defect in the expression of 
these gut-homing molecules on small intestinal IEL and LPL from Itk-/- compared 
to WT mice, a defect that could also be seen on Itk-/- CD8+ T cells in the mLN 
(Fig. 4.8C and D). These data strongly suggest that the reduced numbers of 
CD8+ T cells in the intestinal mucosa of Itk-/- mice is due to impaired expression of 
gut tissue homing and retention molecules, and that this defect arises during T 
cell priming in the mLN. 
      To test whether ITK signaling during T cell priming in mLN might be required 
for optimal expression of gut-homing molecules on CD8+ T cells, I performed in 
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vitro stimulation experiments. For these studies, I compared WT OT-I CD8+ T 
cells stimulated with mLN DCs versus splenic DCs pulsed with two doses of a 
moderate affinity peptide ligand for OT-I cells, the T4 variant of SIINFEKL 
(SIITFEKL). In addition, cultures were treated or not with a small molecule ITK 
inhibitor (PRN694) (Zhong et al., 2015). Previous studies have shown that mLN-
derived DCs produce factors important in upregulating gut-homing molecules 
(Gorfu et al., 2009; Svensson et al., 2008). As shown, OT-I cells stimulated with 
APCs from mLN show robust upregulation of CD103, CCR9 and integrin α4β7 
(Fig. 4.9A and B). This upregulation is significantly reduced when ITK is inhibited 
by PRN694. As a control, fewer OT-I cells stimulated with peptide on splenic 
APCs upregulate these gut-homing receptors; further, the response in these 
cultures is not ITK-dependent. These data demonstrate that ITK signaling is 
required for optimal induction of gut-homing receptors in CD8+ T cells after 
priming in vitro with DCs from mLN, suggesting that this response is likely 
impaired during mLN priming in vivo. 
 
G. ITK is required for optimal expression of gut-homing receptors 
Reduced expression of gut-homing receptors on Itk-/- T cells in vivo suggested 
that ITK might be involved in the upregulation of these molecules following T cell 
activation, leading to a defect in migration or retention of effector CD8+ T cells in 
this tissue. To determine whether Itk-/- T cells were impaired in their ability to 
migrate into gut tissue, I stimulated WT and Itk-/- OT-I T cells with anti-CD3 mAb  
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Figure 4.8. Gut-resident and mesenteric lymph node CD8+ T cells in Itk-/- mice 
have reduced gut-homing receptor expression 
(A-D) Expression of CD69 versus CD103 (A) and integrin α4β7 versus CCR9 (C) 
on CD8+ T cells from intestinal tissues (siIEL, cIEL, siLPL, and cLPL) and 
mesenteric lymph node (mLN) of uninfected WT and Itk-/- mice. Graphs show 
compilation of percentages of CD8+ T cells in mLN that are CD103+ (B) and 
integrin α4β7+ CCR9+ (D) in uninfected naïve WT and Itk-/- mice. Data shown are 
representative of five mice of each genotype (mean ± SEM). 
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Figure 4.9. ITK inhibition leads to a reduction in gut-homing receptor expression 
in CD8+ T cells 
(A-B) OT-I WT CD8+ T cells were co-cultured in the presence of splenic DCs 
(Spl-DC) or mLN-derived DCs (mLN-DC) pulsed with T4-OVA peptide (low, 5.0 
pM or high, 200 pM) for 48 h, and the expressions of CD103, CCR9, and integrin 
α4β7 were analyzed (A). Compilation data of the expression of gut-homing 
receptors are shown (B).   
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plus TGF-β and/or RA for 48 h in vitro and then examined the cells for expression 
of CD103, CCR9, and integrin α4β7. In the absence of TCR stimulation, neither 
WT nor Itk-/- OT-I T cells expressed these molecules. Following TCR stimulation 
alone, WT OT-I T cells exhibited a modest upregulation of these receptors, 
whereas on average, upregulation of these receptors was reduced on Itk-/- OT-I T 
cells. This defect in Itk-/- OT-I cells was more pronounced when cells were 
stimulated with anti-CD3 plus RA and TGF-β (Fig. 4.10A and B). The impaired 
upregulation of gut-homing receptors observed on Itk-/- OT-I cells was not a 
consequence of choosing a single dose of RA or TGF-β, as extensive titrations of 
these compounds failed to alter the responses of Itk-/- OT-I cells (Fig. 4.11A-F). I 
also assessed expression of TGF-β and RARα, to determine whether impaired 
receptor expression might account for the reduced responses of Itk-/- OT-I cells to 
these compounds. While I observed an interesting dose-response effect of RA on 
the expression of Tgfbr2, in the presence of the standard doses of RA (10nM) 
and TGF-β (5.0 ng/mL) used in the functional studies, no significant differences 
in Tgfbr2 or Rara mRNA levels were observed when comparing WT and Itk-/- OT-I 
cells (Fig. 4.11G and H). Overall, these data confirm that Itk-deficient OT-I cells 
have an impaired response to TCR stimulation plus RA and TGF-β. 
 
H. ITK is required for acquisition of in vivo gut-homing properties 
Next, I sought to determine if this defect in gut-homing receptors would lead to a 
homing defect in vivo. To test this, I stimulated WT or Itk-/- OT-I cells with anti- 
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Figure 4.10. ITK regulates gut-homing receptor expression in CD8+ T cells in the 
presence of RA and TGF-β 
(A-B) OT-I WT and Itk-/- CD8+ T cells were stimulated with anti-CD3 (1.0 μg/mL) 
in the presence or absence of TGF-β (5.0 ng/mL) plus RA (10nM) for 48 h, and 
CD103, CCR9, and integrin α4β7 expression were examined (A). Compilation of 
data from two independent experiments is shown (B). 
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Figure 4.11. Itk-/- CD8+ T cells display reduced gut-homing receptor expressions 
regardless of the dosage RA and TGF-β 
(A-F) Isolated WT and Itk-/- OT-I CD8+ T cells were stimulated with anti-CD3 (1.0 
μg/mL) in the presence or absence of TGF-β (0.5 to 10.0 ng/mL) plus RA (10nM 
or 1.0 to 50nM) for 48 h, and CD103 (A-B), CCR9 (C-D), and integrin α4β7 (E-F) 
expression were examined. (G-H) mRNA expression of Tgfbr2 (G) and Rara (H) 
WT Itk-/-
anti-CD3 + RA (nM)
WT Itk-/-
anti-CD3 + RA + TGF-β (ng/mL)A B
C D
E F
CD103 CD103
CCR9 CCR9
Integrin α4β7 Integrin α4β7
G H
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from the same experiments are shown. Data are compiled from 2-3 independent 
experiments.  
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CD3 in the presence of RA (10nM) and TGF-β (5.0 ng/mL) for 48 h, and then 
adoptively transferred the cells to congenic naïve WT recipients. Analysis of the 
activated cells immediately prior to transfer confirmed that WT cells stimulated 
with TCR plus TGF-β and RA upregulated high levels of CD103 and CCR9 
compared to cells stimulated through the TCR alone. In contrast, upregulation of 
these receptors on Itk-/- T cells was markedly reduced. Expression of integrin 
α4β7 in WT OT-I T cells was comparable in either the presence or absence of 
RA and TGF-β under TCR stimulation conditions. Interestingly, Itk-/- OT-I T cells 
also displayed impaired integrin α4β7 expression following stimulation (Fig. 
4.10A and B). Three days after cell transfer, recipient mice were sacrificed, and 
OT-I T cell proportions in the spleen, mLN, and small intestinal LPL and IEL 
compartments were determined. No differences were seen between WT and Itk-/- 
OT-I T cells in the spleen or mLN, regardless of stimulation conditions (Fig. 
4.12A-C). When recipient mice received WT OT-I cells that had been stimulated 
with anti-CD3 plus TGF-β and RA, substantial populations of transferred cells 
were detected in the intestinal tissue, particularly in the small intestine LPL 
compartment, compared to mice receiving WT OT-I cells that had been primed in 
vitro with anti-CD3 stimulation alone. Recipients receiving Itk-/- T cells had few 
transferred cells in the intestinal tissue, regardless of whether TGF-β and RA 
were present during their initial stimulation. Consistent with these data, CD69 
and CD103 expression (Fig. 4.13A and B), as well as integrin α4β7 and CCR9 
(Fig. 4.13C and D), were elevated on WT versus Itk-/- OT-I T cells recovered from  
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Figure 4.12. ITK regulates the migration of CD8+ T cells to the intestine 
(A-C) Congenically labeled OT-I WT (CD45.2) and Itk-/- (CD45.1) CD8+ T cells 
were stimulated with anti-CD3 (1.0 μg/mL) with or without TGF-β (5.0 ng/mL) 
plus RA (10nM) for 48 h. Cells (6.0 x 106 cells) were then adoptively transferred 
to uninfected congenic hosts and donor T cells in the spleen or mLN (top, left) (A) 
and small intestine lamina propria or epithelium (bottom, left) (B) were analyzed 
at D3 post-transfer. Compilation of data from two independent experiments is 
shown; each data point represents an individual recipient (C).  
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Figure 4.13. Impaired migration of Itk-/- CD8+ T cells to the intestine is associated 
with a reduction in gut-homing receptor expression 
(A-D) Congenically labeled OT-I WT (CD45.2) and Itk-/- (CD45.1) CD8+ T cells 
stimulated with anti-CD3 (1.0 μg/mL) in the presence or absence of TGF-β (5.0 
ng/mL) plus RA (10nM) for 48 h were adoptively-transferred into uninfected WT 
recipients. Transferred T cells were isolated from the indicated tissues at D3 
post-transfer and analyzed for expression of CD69 versus CD103 (A-B) or 
integrin α4β7 versus CCR9 (C-D). Compilations of CD69+ CD103+ (B) or integrin 
 88 
α4β7+ CCR9+ (D) percentages of CD8+ T cells from flow cytometric analyses are 
shown in the graphs at the right. 
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siLP and siIEL at day 3 post-transfer, particularly on cells primed in vitro in the 
presence of TGF-β and RA. These data indicate that ITK is required for CD8+ T 
cells to acquire gut-homing properties in response to TCR plus TGF-β and RA 
stimulation in vitro, and that ITK functions in the upregulation of gut homing 
receptors during T cell priming. 
 
I. Enforced expression of IRF4 in Itk-/- CD8+ T cells restores migration to the 
intestine 
Based on the data presented above, I considered how ITK signaling might 
regulate gut-homing properties of effector CD8+ T cells. One likely candidate to 
mediate this function was the transcription factor IRF4, known to be induced by 
TCR signaling in an ITK-dependent pathway (Nayar et al., 2012). I first examined 
IRF4/BATF binding sites on the Ccr9, Itgae, Itga4 and Itgb7 loci in activated T 
cells utilizing published datasets (Iwata et al., 2017; Wang et al., 2013). As 
shown in Fig. 4.14A, both Ccr9 and Itga4 appear to have prominent IRF4/BATF 
binding sites. To test whether IRF4 expression levels might be important in 
programming activated CD8+ T cells for gut-homing, I assessed steady-state T 
cell numbers in the small intestine of Irf4 heterozygous mice (Irf4+/fl), in which 
TCR-dependent IRF4 expression levels are reduced, but not abolished (Man et 
al., 2013; Nayar et al., 2014). Due to a dysregulated immune system in 
homozygous Irf4fl/fl mice, mice bearing T cells lacking all IRF4 expression were 
not examined. In Irf4+/fl mice steady-state numbers of CD4+ T cells in the small 
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intestinal epithelium and lamina propria were comparable to wild-type littermate 
controls. In contrast, I observed reduced proportions and numbers of Irf4+/fl CD8+ 
T cells in the IEL and LPL compared to controls (Fig. 4.14B and C). When 
assessed for CD103, CCR9, and integrin α4β7 expression, I also found that 
CD8+ T cells from the small intestine of Irf4+/fl had reduced expression of CD103 
compared to wild-type cells, but no change in expression of CCR9 or integrin 
α4β7 (Fig. 4.14D and E). 
      To assess more directly whether optimal expression of IRF4 is important in 
regulating gut-homing receptor expression during T cell activation, I tested Irf4+/fl 
CD8+ T cells for their in vitro responses to stimulation in the presence of RA or 
TGF-β. Consistent with the data shown above for Irf4+/fl CD8+ T cells analyzed 
directly ex vivo from the small intestine, I observed reduced expression of CD103 
on Irf4+/fl CD8+ T cells compared to control T cells in response to varying doses 
(0.5 to 5.0 ng/mL) of TGF-β (Fig. 4.15A and B). Parallel studies examining the 
responsiveness of CCR9 and integrin α4β7 to RA revealed reduced CCR9 
expression by Irf4+/fl CD8+ T cells compared to WT controls in the presence of low 
levels of RA (Fig. 4.15A C and D), but no consistent differences in integrin α4β7 
expression (Fig. 4.15A E and F). These correlative data suggested a mechanistic 
link between ITK signaling and IRF4 upregulation in the priming of efficient gut-
homing CD8+ effector T cells. 
      These findings prompted us to test whether enforced expression of IRF4 
could restore efficient gut-homing properties to Itk-/- CD8+ T cells. For these  
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Figure 4.14. Irf4+/- mice show a reduction in CD8+ T cell number in the gut 
(A) ChIP-Seq analysis of the binding of BATF and IRF4 to genomic regions in the 
proximity of Ccr9, Itgae, Itga4, and Itgae from NCBI GEO Database. (B-C) The 
proportions (B) and numbers (C) of CD8+ and CD4+ T lymphocytes (gated on 
TCRβ+) from the siIEL and siLPL of Irf4+/+ and Irf4+/fl mice. (D-E) Expression of 
CD69 versus CD103 or integrin α4β7 versus CCR9 from CD8+ T cells from siIEL 
and siLPL of Irf4+/+ and Irf4+/fl mice (D). Mean fluorescence of each molecule was 
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enumerated at the bottom (E). Data shown are compilations of 5-7 mice of each 
genotype from 2-3 independent experiments.   
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Figure 4.15. IRF4 have a functional correlation with the regulation of gut-homing 
receptor expression in CD8+ T cells 
(A-F) Spleen Irf4+/+ and Irf4+/fl CD8+ T cells were stimulated with anti-CD3 ± 
varying concentrations of TGF-β (0.2 to 5.0 ng/mL) or RA (0.1 to 2.0 nM) for 48 
h, and CD103 (A), CCR9 (B), and integrin α4β7 (C) expression were analyzed. 
Mean fluorescence of each molecule was enumerated in the graph at the right. 
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studies, WT and Itk-/- OT-I CD8+ T cells were activated in vitro and then 
transduced with a retrovirus carrying GFP alone (empty vector, EV) or GFP plus 
IRF4 (IRF4). Following this, transduced T cells were cultured with RA and TGF-β 
for 48 h, and then adoptively transferred into congenic naïve WT hosts. Three 
days after transfer, recipient mice were analyzed for OT-I T cells in the small 
intestine. As shown in Fig. 4.16A, WT and Itk-/- OT-I cells were expressing 
comparable levels of GFP from the empty vector, or the IRF4 virus, respectively. 
I then assessed the expression levels of IRF4 in both WT and Itk-/- OT-I T cells 
(Fig. 4.16B). As expected, Itk-/- T cells transduced with empty virus expressed 
lower levels of IRF4 compared to WT T cells, and in both cases, IRF4 expression 
levels were increased in cells transduced with the IRF4-expressing virus (Fig. 
4.16B). Next, I assessed the localization of the transferred cells in the recipients. 
I first observed increased proportions of IRF4 transduced CD8+ T cells in mLN of 
hosts compared to cells transduced with empty vector (Fig. 4.16C and D). This 
increase was seen for both WT and Itk-/- cells. Examination of transferred cells in 
the small intestinal lamina propria indicated substantial improvement in the gut-
homing capacity of Itk-/- CD8+ T cells when transduced with the IRF4 virus 
compared to the empty vector; in these studies, enforced IRF4 expression 
restored the gut-homing of Itk-/- CD8+ T cells to that seen for empty virus-
transduced WT T cells. Further supporting a key role for IRF4 in regulating gut-
homing properties of CD8+ T cells, even WT T cells transduced with the IRF4 
virus showed improved gut-homing compared to cells transduced with empty 
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vector. Interestingly, this improved gut-homing capability via IRF4 overexpression 
in Itk-/- T cells was correlated with enhanced gut-homing receptor expressions 
upon RV transduction (Fig. 4.16E and F). Together, these data confirm that 
optimal IRF4 expression is critical for gut-homing of effector CD8+ T cells, and 
support the conclusion IRF4 expression levels provide the link between TCR 
signaling mediated by ITK to the migration of CD8+ T cells to the intestine by 
inducing optimal expression of gut-homing receptors. 
 
J. Discussion to Chapter IV 
In this chapter, I show that mice lacking ITK have a dramatic reduction in tissue-
resident T cells in the intestinal mucosa, and that as a consequence, Itk-/- mice 
are unable to mount a protective immune response to a viral infection in the 
gastrointestinal tract. Previous studies have shown that long-term maintenance 
of CD8+ TRM in mucosal tissues provides for an immediate protective response 
against reinfection by the same virus or due to reactivation of a latent virus 
(Khanna et al., 2003; Knickelbein et al., 2008; Liu et al., 2001; Sheridan et al., 
2014). TRM are also known to express constitutively high levels of cytolytic 
molecules, such as granzyme B and perforin, despite the absence of antigen 
after viral clearance (Casey et al., 2012). These data support the notion that the 
lack of gut-resident CD8+ T cells in Itk-/- mice is responsible for the ongoing 
uncontrolled replication of MHV68 in this tissue. Consistent with this, the 
pathology showing tissue disruption was only observed in the intestine but not in  
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Figure 4.16.  Enforced expression of IRF4 restores Itk-/- CD8+ T cell migration to  
the intestine 
(A-B) RV transduction efficiency (GFP+) (A) and IRF4 expression (B) of WT and 
Itk-/- CD8+ T cells from small intestine LP at D3 of post-transfer are shown. No RV 
control shows the level of IRF4 expression in naïve WT CD8+ T cells from siLPL. 
(C-F) RV-transduced (Empty vector or IRF4) congenically-labeled WT (CD45.2) 
and Itk-/- (CD45.1) CD8+ T cells were primed with RA and TGF-β for 48 h and 
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then adoptively transferred (4.0 x 107) to congenic WT naïve host. Transferred T 
cells were isolated from mesenteric lymph node (left panel) and small intestinal 
LP (right panel) at D3 post-transfer (C). Compilation data from 4-5 mice per each 
group from 2-3 independent experiments are shown at the right (D). The 
expression of CD69 versus CD103 (left panel) or integrin α4β7 versus CCR9 
(right panel) in transferred T cells in small intestinal LP is shown (E). Mean 
fluorescence of each molecule was enumerated in the graph at the right (F). 
  
 98 
other organs (e.g. spleen or lung). While this gut-associated pathology could be 
associated with a difference in the microbiome of Itk-/- compared to WT mice bred 
in our vivarium, preliminary data using q-PCR or 16S rRNA gene sequencing did 
not reveal any detectable compositional differences. Nonetheless, future studies 
are warranted to determine whether differences in intestinal microbiota can 
impact anti-viral immune responses to MHV68 in the gastrointestinal tract. 
      Although Itk-/- mice have a steady-state deficiency in gut-resident T cells, I do 
not observe spontaneous gastrointestinal disease in uninfected Itk-/- mice. 
Furthermore, administration of a single subclinical dose of LPS (IP) into 
uninfected Itk-/- mice also caused no tissue pathology, in spite of its known effect 
on intestinal epithelial permeability (Bein et al., 2017; Guo et al., 2015). However, 
LPS treatment of latently MHV68-infected Itk-/- mice caused a massive disruption 
of intestinal epithelium regardless of the route of infection. I reasoned that long-
term persistence of virus in the intestine caused a low level of chronic tissue 
damage, as has previously been reported in mice infected with cytomegalovirus 
(MCMV) (Onyeagocha et al., 2009). Thus, when these mice are treated with 
LPS, the increase in intestinal epithelial permeability induced by the LPS triggers 
an irreparable level of acute tissue damage that is fatal in long-term latently-
infected Itk-/- mice. 
      The data indicate that T cell priming in mesenteric lymph nodes fails to 
upregulate high levels of CD103, integrin α4β7, and CCR9 on Itk-/- CD8+ T cells. 
This defect can be recapitulated by in vitro stimulation of naive Itk-/- OT-I CD8+ T 
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cells in the presence of TGF-β and RA. In addition, transfer of these in vitro-
activated T cells into WT recipients confirms their gut-homing defect. Impaired 
expression of CD103 on primed Itk-/- CD8+ T cells can be explained by the 
demonstrated cooperativity of TGF-β-induced Smad2/3 and TCR-induced NFAT1 
activation for optimal CD103 induction (Mokrani et al., 2014), as ITK signaling is 
known to be required for robust TCR-induced NFAT1 activation (Fowell et al., 
1999). However, examination of integrin α4β7 and CCR9 upregulation on cells 
stimulated with varying doses of TGF-β plus or minus RA indicates that Itk-/- CD8+ 
T cells have a more global defect in responding to TGF-β and RA. I tested the 
possibility that this might result from impaired expression of TGF-βRII and/or 
RARα in Itk-/- CD8+ T cells. While I did observe reduced Tgfbr2 mRNA in Itk-/- 
CD8+ T cells stimulated with low concentrations of RA, no impairment in Tgfbr2 
expression was seen in Itk-/- CD8+ T cells when stimulations were performed in 
the presence of TGF-β plus RA. For Rara mRNA expression, I did observe 
modest reductions (2-3-fold) in Itk-/- compared to WT T cells after stimulation 
through the TCR plus TGF-β and RA, but have no direct evidence that this 
difference is functionally relevant. As an alternative, I suggest that Itk-/- CD8+ T 
cells may lack other factors required for optimal responses to TGF-β and RA. For 
instance, Smad3, which required for TGF-βRII signaling, is known to be 
upregulated during T cell activation (Zloza et al., 2011). Thus, activated Itk-/- CD8+ 
T may have lower levels of Smad3 than WT T cells, leading to a deficiency in 
responding to TGF-β. For responses to RA, three isoforms of RAR and its 
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binding partner, RXR, have been identified. A deficiency in expressing an 
alternative isoform of RAR, or one of the RXR isoforms, could also account for 
the poor responses of activated Itk-/- CD8+ T cells to RA.  
      Based on the clinical reports of EBV-induced lymphoproliferative disease 
patients with ITK mutations, it is unknown whether these patients suffered from 
any symptoms related to gastrointestinal pathology prior to their identification as 
lymphoproliferative disease patients (Ghosh et al., 2014; Huck et al., 2009; Linka 
et al., 2012; Mansouri et al., 2012; Stepensky et al., 2011). However, EBV 
infection is also associated with gastrointestinal tissue diseases, such as gastric 
carcinoma and esophageal cancer (Kume et al., 1999; Mori et al., 1994). In 
addition, one recent report revealed that a Helicobacter pylori-derived metabolite 
induces EBV reactivation in the gastric epithelium (Minoura-Etoh et al., 2006). As 
MHV68 can persist in lung epithelial cells (Stewart et al., 1998), it is possible that 
MHV68 can also persist in the gut epithelium. Thus, I conclude that the intestinal 
pathology I observed in latently infected Itk-/- mice was primarily due to lytic viral 
replication (Barton et al., 2011). Overall, these findings provide a strong rationale 
for investigating ITK genetic status in EBV-positive patients suffering from 
chronic gastrointestinal diseases or from gastric cancers. 
      Transcriptome analyses of tissue-resident T cells in the brain or lung tissues 
of humans and mice have revealed that IRF4 is one of the most highly 
upregulated transcription factors in these cells (Kumar et al., 2017; Landrith et 
al., 2017; Wakim et al., 2012). However, detailed functional studies of IRF4 in T 
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cell homing to mucosal barriers have not been reported, although one study 
examined IRF4 in the development of VAT tissue Tregs (Vasanthakumar et al., 
2015). Thus, these data provide new insights into how TCR signaling via the ITK-
IRF4 axis control the migration of CD8+ T cells to the intestine. Interestingly, 
Kurachi et al. and others have found that IRF4/BATF bind directly to the 5′ 
upstream regions of gut-homing molecule genes (e.g. Ccr9 and Itga4) (Iwata et 
al., 2017; Kurachi et al., 2014; P. Li et al., 2012). Furthermore, BATF, the most 
important binding partner of IRF4, is known to be required for the expression of 
CCR9 and integrin α4β7 in response to RA in CD4+ T cells, and Batf-deficient T 
cells are greatly impaired in trafficking to the small intestine (Wang et al., 2013). 
While I have not tested whether enforced expression of BATF would also restore 
gut homing potential to Itk-/- T cells, I reasoned that IRF4 was a more likely 
candidate in this setting due to the greater magnitude of Irf4 induction after TCR 
stimulation compared to BATF (www.immgen.org). Additionally, our previous 
data connect ITK signaling to the magnitude of IRF4 upregulation (Nayar et al., 
2014; 2012). Importantly, a recent study reported that IRF4 haploinsufficiency in 
humans leads to severe gastrointestinal inflammation due to an impaired control 
of the enteric bacteria, Tropheryma whipplei (Guérin et al., 2018), While this 
clinical report did not directly assess whether patients exhibited impaired T cell 
homing the intestine, this study provides a potential mechanism to account for 
the susceptibility in patients carrying a single allele deficiency in IRF4.  
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CHAPTER V: THE TEC KINASE ITK REGULATES TYPE 2 INNATE 
LYMPHOID CELLS IN THE INTESTINE AND PROMOTES 
INTESTINAL TISSUE INTEGRITY 
 
Innate lymphoid cells are one of specialized group of lymphocytes that are 
preferentially located at mucosal tissue barriers, such as skin, lung and intestine. 
Recent studies have suggested that ILC subsets functionally matched with T 
helper cells according to their effector molecules and also lineage-defining 
transcription factors (Artis and Spits, 2015; Diefenbach et al., 2014; Spits and 
Cupedo, 2012; Zook and Kee, 2016). Although innate lymphoid cells have no 
antigen-specific receptors, they express a range of TCR signaling molecules, and 
these molecules have been implicated in ILC activation (Choi et al., 2015; 
Steinke and Xue, 2014; Weber et al., 2011; Yang et al., 2015; 2013). However, a 
precise role of these molecules in innate lymphoid cells has not clearly 
demonstrated. Interestingly, among innate lymphoid cell subsets, the Tec family 
kinase ITK is highly expressed in ILC2, but not in other ILCs (Shih et al., 2016) 
(www.immgen.org). Given the role of ITK in TH2 response and the functional 
similarity between TH2 and ILC2 (Hoyler et al., 2012; Klose and Artis, 2016; Miller 
et al., 2004; Schaeffer et al., 2001), I hypothesized that ITK might play an 
important role in ILC2. In this chapter of thesis, I examined how Itk deficiency in 
mice functionally impacts on ILC2 in the intestine, thereby affect intestinal tissue 
homeostasis. 
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A. Itk deficiency leads to a steady-state defect in intestinal ILC2 
Gene expression data indicate that Itk is highly expressed in intestinal ILC2, at 
levels comparable to those seen in CD4+ T cells. Furthermore, high expression of 
Itk was not shared with other innate lymphoid cell subsets, such as ILC1 or ILC3, 
in the intestine (Shih et al., 2016) (www.immgen.org). To determine a function of 
ITK in ILC2, I isolated lamina propria lymphocytes from small and large intestine 
tissues of naïve WT and Itk-/- mice and analyzed intestinal ILC2 (GATA-3+ 
CD127+) populations. In both small and large intestine lamina propria, the 
frequency of ILC2 in Itk-/- mice was significantly reduced 3-6-fold compared WT 
intestinal ILC2 (Fig. 5.1A and B), and the number of ILC2 in both intestinal 
tissues was 6-7-fold lower in Itk-/- mice relative to the number of WT intestinal 
ILC2 (Fig. 5.1C). This deficit in ILC2 was restricted to the intestinal tissues, as 
bone marrow (BM), lung, and mesenteric lymph nodes of Itk-/- mice showed no 
reduction in proportions of ILC2 compared to controls (Fig. 5.1D and E). 
Furthermore, assessment of steady-state populations of intestinal ILC1 (NK1.1+ 
NKp46+), ILC2 (GATA-3+ RORγt-), and ILC3 (GATA-3- RORγt+) examined 
together using the gating strategy outlined in Fig. 5.2A indicated that intestinal 
ILC2 were the only subset profoundly affected by the absence of ITK (Fig. 5.1F 
and Fig. 5.2B). These data demonstrate that Itk deficiency specifically affects the 
ILC2 population in the intestine, but not other ILC populations, or ILC2 in other 
tissue sites. 
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Figure 5.1. Itk-/- mice have a gut-specific reduction in ILC2  
(A-C) The proportions of ILC2 (GATA-3+ CD127+) in lamina propria of the small 
(siLP) or large intestine (cLP) from naïve WT and Itk-/- mice are shown after 
gating on lineage-negative cells (CD3ε- CD19- TCRβ- TCRγδ- CD11b- CD11c-) 
(A). Graphs show compilations of intestinal ILC2 proportions (B) and numbers 
(C) in the siLP and cLP. (D-E) ILC2 proportions from the bone marrow (BM), 
lung, and mesenteric lymph nodes (mLN) of naïve WT and Itk-/- mice (D) along 
siLP cLP
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with compilations of data (E). (F) The proportions of various ILC subsets in the 
siLP and cLP were analyzed. Intestinal ILC2 and ILC3 frequencies were 
enumerated from the gating shown in Fig. 5.2A.  
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Figure 5.2. Gating strategy used to identify multiple ILC subsets in the intestine 
(A) Isolated gut lymphocytes were stained with a set of antibodies to identify 
multiple ILC populations. From a series of dump gates (CD3ε- CD19- TCRβ- 
TCRγδ-, blue box on the left), intestinal ILC1 (NK1.1+ NKp46+) and ILC2 (GATA-
3+ CD127+) were identified. Cells from the dump gates were further gated on 
Figure S1
A
B
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NK1.1- CD127+ cells (red box on the right), and intestinal ILC2 (GATA-3+ RORγt-) 
and ILC3 (GATA-3- RORγt+) are identified. (B) Based on this gating strategy, 
intestinal ILC2 vs ILC3 (left) and intestinal ILC1 from siLP and cLP of WT and Itk-
/- mice are shown.  
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B. Impaired expansion of gut ILC2 in virally-infected Itk-deficient mice 
Pulmonary viral infections have been shown to induce substantial increases in 
lung ILC2 numbers (Gorski et al., 2013; Saravia et al., 2015; Stier et al., 2016). 
To assess the responses of Itk-/- ILC2 to viral infection, I first infected WT and Itk-
/- mice with murine gammaherpesvirus 68 (MHV68) by the intranasal route (1.0 x 
103 PFU). As previously described for RSV or IAV infection, intranasal MHV68 
infection induced a 2-fold increase in lung ILC2 at D7 post-infection, with a 
further increase at D14 post-infection compared to uninfected controls (Fig. 5.3A 
and B versus Fig. 5.1D and E). This response was not altered in the absence of 
ITK. I then challenged WT and Itk-/- mice with MHV68 via intraperitoneal 
inoculation (1.0 x 106 PFU), as MHV68 has been shown to replicate in the 
gastrointestinal epithelium (Hwang et al., 2008; Peacock and Bost, 2000). As 
shown, ILC2 in the lamina propria of small and large intestine of WT mice 
showed a 2-fold increase at D7 of post-infection compared to uninfected controls; 
steady-state proportions of intestinal ILC2 were restored in WT mice by D14 
post-infection (Fig. 5.3C and D versus Fig. 5.1A and B). In contrast, intestinal 
ILC2 in Itk-/- mice remained at low levels after infection, at both D7 and D14 
timepoints (Fig. 5.3C and D). 
      I also examined other ILC subsets in the intestine after MHV68 by 
intraperitoneal inoculation. Although there were modest decreases in ILC3 and 
ILC1 in cLP of Itk-/- mice at D14 post-infection compared to WT, no significant 
differences were consistently observed in intestinal ILC3 or ILC1 in MHV68-
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infected WT versus Itk-/- mice at both timepoints, as was observed for intestinal 
ILC2 (Fig. 5.3E-G). To determine whether gut ILC2 were required for effective 
viral control in the intestine, I challenged Rorafl/fl x Il7ra-Cre mice or littermate 
controls (Rora+/+x Il7ra-Cre and Rora+/fl x Il7ra-Cre) with IP MHV68 infection, as 
Rorafl/fl x Il7ra-Cre mice are known to lack ILC2 in all tissues (Oliphant et al., 
2014). Despite this ILC2 deficiency, Rorafl/fl x Il7ra-Cre mice had similar MHV68 
viral genome copy numbers in both spleen and small/large intestine at D14 post-
infection compared to controls (Fig. 5.4A and B). Collectively, these data indicate 
that an intestinal ILC2 deficit in Itk-/- mice does not affect the control of MHV68 
replication in the gut epithelium. 
 
C. Itk-deficient ILC2 precursors in the bone marrow have normal gut-homing 
receptor expression 
Examination of ILC2 in the bone marrow showed a modest increase in the 
proportions of these cells in Itk-/- mice compared to WT (Fig. 5.1D and E). To 
assess whether ITK might function in ILC2 development, I performed additional 
characterization of ILC2 precursors in the bone marrow. After depleting lineage-
positive bone marrow cells, I compared the frequencies and numbers of bone 
marrow ILC2 precursors in naïve WT and Itk-/- mice. Similar to the findings shown 
above in the absence of lineage-positive bone marrow cell depletion (Fig. 5.1D 
and E), lineage-depleted bone marrow cell population analyses revealed modest 
increases in the frequency and cellularity of Itk-/- bone marrow ILC2 precursors  
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Figure 5.3. Impaired expansion of intestinal ILC2 in virus-infected Itk-/- mice 
(A-B) Lung ILC2 proportions in WT and Itk-/- mice at D7 and D14 of post-infection 
following intranasal infection with MHV68 (1.0 x 103 PFU/mouse) (A). Compiled 
data from 6 mice per group are shown (B). (C-D) Intestinal ILC2 from siLP or cLP 
of WT and Itk-/- mice at D7 and D14 following IP infection with MHV68 (1.0 x 106 
PFU/mouse) (C). Compiled data from 5 mice per group (D). (E-G) Intestinal ILC 
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subsets were analyzed before (D0) and after MHV68 intraperitoneal infection (D7 
or D14). Gating strategies are as shown in Figure 5.2A.  
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Figure 5.4. ILC2 deficiency does not affect the control of MHV68 in the intestine 
(A-B) Viral copy numbers of MHV68 DNA in the spleen (A) and the small or large 
intestine (B) of littermates that were Rora+/+, Rora+/fl, and Rorafl/fl crossed to Il7ra-
Cre are shown at D7 post-infection. 
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compared with WT bone marrow ILC2 precursors (Fig. 5.5A and B). However, 
the magnitude of these changes was far smaller than the reduction in ILC2 
numbers seen in the intestinal tissue of Itk-/- mice (Fig. 5.1A-C). 
      Compared to other ILC subsets, ILC2 precursors in the bone marrow have 
been shown to express gut-homing receptors, CCR9 and integrin α4β7, and to 
traffic efficiently to the intestine without requiring priming or in secondary 
lymphoid organs, such as gut-draining LNs (Hoyler et al., 2012; C. H. Kim et al., 
2016; M. H. Kim et al., 2015). Therefore, I examined gut-homing receptor 
expression on bone marrow ILC2P from WT and Itk-/- mice. As shown, I did not 
observe any significant differences in the expression of CCR9 and integrin α4β7 
between WT ILC2 precursors and Itk-/- ILC2 precursors in the bone marrow (Fig. 
5.5C and D). I also examined ILC2-associated cytokine receptors, IL-25R (IL-
17RB), IL-33R (T1/ST2), and CD25 (Fig. 5.5E and F), and surface markers, 
CD90, Sca-1, and KLRG-1 (Fig. 5.5G and H). While I found modest reductions of 
IL-33R and CD25 expression on Itk-/- ILC2 precursors in the bone marrow 
compared with controls, the magnitude of these changes was small. Taken 
together, these data overall do not reveal major differences between WT and Itk-/- 
ILC2 precursors in the bone marrow. Furthermore, the data indicate that the 
absence of ITK is not likely to affect the gut-homing potential of ILC2 generated 
in the bone marrow, at least not due to altered expression of gut-homing 
receptors. 
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Figure 5.5. Bone marrow ILC2 precursors in Itk-/- mice exhibit normal gut-homing 
receptor expression 
(A-B) The proportions and numbers of WT and Itk-/- ILC2 precursors were 
analyzed from lineage depleted BM cells. (C-H) The expression of gut-homing 
receptors, CCR9 and integrin α4β7 (C-D, top panel), cytokine receptors, IL-25R, 
IL-33R, and CD25 (E-F, middle panel), and ILC2 markers, CD90, Sca-1, and 
KLRG-1 (G-H, bottom panel), on WT and Itk-/- BM ILC2P were analyzed. 
Compiled MFIs from 2 to 3 independent experiments are shown in the graphs (D, 
F, H).   
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D. ITK is not required for expression of gut-homing receptors on gut ILC2 
To investigate further a potential role for ITK in gut-homing receptor expression 
on ILC2, I assessed CCR9 and integrin α4β7 levels on ILC2 in the small and 
large intestinal lamina propria from naïve WT and Itk-/- mice. In spite of being 
present at reduced cellularity, the expression levels of homing receptors on Itk-/- 
ILC2 from the small intestinal LP were similar to those on WT ILC2 from this site 
(Fig. 5.6A and B, left panel). In the colonic LP, CCR9 expression on Itk-/- ILC2 
showed was modestly reduced compared to that on WT cLP ILC2, whereas 
integrin α4β7 expression levels were similar (Fig. 5.6A and B, right panel).  
      As previously reported, RA is not required for the expression of gut-homing 
receptors nor for the tissue homing ability of ILC2 to the intestine (M. H. Kim et 
al., 2015). Nonetheless, I investigated the effects of TGF-β and/or RA on ILC2 
gut-homing receptor expression in the absence of ITK. For this analysis, I 
isolated lineage-depleted WT and Itk-/- bone marrow cells and cultured them in 
vitro with IL-2, IL-7, and IL-33 in presence of RA and/or TGF-β for 5 d. As shown, 
and consistent with previously reported data (M. H. Kim et al., 2015), I did not 
observe any detectable differences in integrin α4, integrin β7, or CCR9 
expression on cultured BM ILC2 precursors in response to RA alone, nor did I 
observe differences between WT and Itk-/- BM ILC2 precursors (Fig. 5.6C and F-
H). TGF-β alone had divergent effects on integrin α4 and integrin β7 in both WT 
and Itk-/- BM ILC2 precursors (Fig. 5.6D and F-H). In combination, RA plus TGF-β 
induced both CCR9 and integrin α4β7 on cultured BM ILC2P, with only modest 
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differences seen by cultured BM ILC2P from WT versus Itk-/- mice (Fig. 5.6E and 
F-H). Taken together, these data indicate that ITK is not strongly regulating the 
expression levels of gut-homing receptors on ILC2 in response to RA and TGF-β 
stimulation. 
 
E. Responses of ILC2 to IL-33 stimulation are modestly impacted by ITK  
Based on the findings that in Itk-/- ILC2 modest reductions in IL-33R expression, I 
considered whether these cells might show impaired responses to IL-33. To 
determine this, I cultured lineage-depleted BM cells with IL-2 plus increasing 
doses of IL-33 (5.0 to 50 ng/mL) for 2 days and compared the expansion of ILC2 
in the populations of lineage-depleted WT and Itk-/- BM cells. In the presence of 
IL-2 plus IL-33, both lineage-depleted WT and Itk-/- BM cells showed a 
comparable ILC2 induction in response to comparatively low IL-33 
concentrations (5.0 to 25 ng/mL); however, at the highest dose of IL-33 (50 
ng/mL) I observed a modest reduction in the proportions of ILC2 in Itk-/- BM 
versus control BM cultures (Fig. 5.7A and B). Next, I assessed the proliferation of 
BM-derived ILC2P in response to IL-33. I labeled lineage-depleted BM cells with 
CellTrace Violet and compared proliferation in response to IL-33 after 2 days in 
the presence of IL-2 ± IL-33. IL-33 induced substantial cell proliferation of WT BM 
cells. In contrast, lineage-depleted Itk-/- BM cells underwent significantly less 
proliferation (Fig. 5.7C). Analyses of the percentages of cells in each division 
peak confirmed that Itk-/- BM cultures had increased proportions of undivided cells  
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Figure 5.6. ITK is not required for gut-homing receptor expression in intestinal 
ILC2 and bone marrow ILC2 precursors 
(A-B) The expression of CCR9 and integrin α4β7 on siLP or cLP ILC2 were 
analyzed (A). Compilation MFI data from three independent experiments are 
shown (B). (C-H) Lineage-depleted BM cells were cultured for 5 d in vitro with IL-
2, IL-7, and IL-33 in the presence of RA and/or TGF-β. Levels of integrin α4 (left 
panel, top to bottom), integrin β7 (middle panel, top to bottom), and CCR9 (right 
panel, top to bottom) on cultured BM ILC2 precursors after RA alone (top row), 
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TGF-β (middle row), or RA plus TGF-β (bottom row) are shown (C-E). 
Compilation of MFI from two independent experiments ware shown (F-H).  
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and had reduced percentages of cells in peaks representing 2-4 cell divisions 
compared to controls (Fig. 5.7D). 
      As I observed modest increases in the numbers of Itk-/- ILC2P in the BM 
compared to controls (Fig. 5.5A and B), and reduced expression of IL-33R on 
these cells (Fig. 5.5E and F), I considered whether ITK might regulate BM egress 
of ILC2 precursors via expression of CXCR4. CXCR4 has been found to promote 
tissue retention of lymphocytes in the bone marrow (Griffith et al., 2014). 
Therefore, I compared CXCR4 expression of untreated BM ILC2P directly ex vivo 
from naïve WT and Itk-/- mice and also examined CXCR4 expression after culture 
of lineage-depleted BM cells with IL-2 for 48 h. I found no differences in CXCR4 
expression on Itk-/- versus WT BM ILC2P directly ex vivo, and a slight reduction 
on Itk-/- BM ILC2P after culture in IL-2 (Fig. 5.7E and F). I then assessed whether 
Itk-/- BM ILC2P showed impaired CXCR4 downregulation after culture in IL-33, as 
this response was reported as a mechanism controlling ILC2P egress from the 
bone marrow (Stier et al., 2018). To test this hypothesis, I cultured lineage-
depleted WT BM cells with IL-2 plus varying doses of IL-33 (1.0 to 10 ng/mL) in 
the presence or absence of PRN694 (25 or 50 nM), an ITK small molecule 
inhibitor. After 2 days, cells were examined for CXCR4 expression. In this setting, 
IL-33 did not promote CXCR4 downregulation on ILC2 precursors in cultured 
lineage-depleted BM cells; however, ITK inhibition did promote a modest 
upregulation of CXCR4 in the presence of a high dose of IL-33 (10 ng/mL) (Fig. 
5.7G and H). Taken together, these data indicate that the absence or inhibition of 
 121 
ITK has a modest effect on IL-33-induced ILC2 proliferation and only very subtle 
effects on CXCR4 expression. 
      Lastly, I tested the efficacy of IL-33-driven ILC2 induction in vivo by injecting 
IL-33 into WT and Itk-/- mice, and then assessing the frequencies of ILC2 in 
various organs. As expected, IL-33 injection increased the ILC2 frequencies in 
mLN and peritoneal cavities of WT mice, with a similar magnitude of change 
seen in Itk-/- mice (Fig. 5.8). These results indicate that Itk-/- ILC2 have no intrinsic 
defect in responding to IL-33 in vivo. Interestingly, however, IL-33 injection failed 
to induce intestinal ILC2 increases in siLP and cLP of Itk-/- mice, whereas WT 
mice showed clear increases in ILC2 in these tissues (Fig. 5.8). These data 
indicate IL-33 injection in vivo is not sufficient to induce an effective ILC2 
population increase in the intestines of Itk-/- mice. 
 
F. Itk deficiency leads to a cell-intrinsic defect in ILC2 tissue maintenance 
in the intestine 
Overall findings with BM ILC2 precursors indicated that the absence of ITK was 
not profoundly affecting ILC2 maturation. Nonetheless, Itk-/- mice consistently 
exhibited a defect in intestinal ILC2 that could not be restored by in vivo 
administration of IL-33. I considered whether this gut-specific defect in ILC2 
might result from impaired migration to the intestine, despite unremarkable 
differences between WT and Itk-/- ILC2 in gut-homing receptor expression. To 
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examine this, I cultured lineage-depleted WT and Itk-/- BM cells with IL-2, IL-7 and 
IL-33 in the presence of RA plus TGF-β, to fully induce gut-homing receptors in  
 
Figure 5.7. ILC2 responses to IL-33 stimulation are modestly impaired in the 
absence of ITK 
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 (A-B) Lineage-depleted WT and Itk-/- BM cells were cultured with IL-2 plus IL-33 
(5.0 to 50 ng/mL) for 2 d and analyzed for ILC2 precursors (A). Compiled data 
from two independent experiments are shown (B). (C-D) Lineage-depleted WT 
and Itk-/- BM cells were labeled with CellTrace Violet and assessed for IL-33-
induced proliferation after 2 d culture (C). Compiled percentage of cells in each 
cell division peak from two individual experiments is shown (D). (E-H) CXCR4 
expression on lineage-depleted BM WT and Itk-/- ILC2 precursors was analyzed 
in the presence or absence of IL-2 after 2 d culture (E). Compiled MFIs from 
three independent experiments are shown (F). CXCR4 expression on cultured 
BM WT ILC2P was analyzed in the presence or absence of PRN694 after culture 
with IL-2 and IL-33 for 2 d (G). Calculated MFIs from the compilation of two 
experiments are shown (H). 
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Figure 5.8. IL-33 injection fails to increase intestinal ILC2 in Itk-/- mice 
Mice were injected daily with IL-33 for 7d, and the percentages of ILC2 from 
mesenteric lymph nodes, peritoneal cavity exudates, and small and large 
intestinal lamina propria were assessed. Data were compiled from three 
independent experiments.   
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vitro. After culture for 3 d, I enriched cultured cells with CD25 MicroBeads to 
further isolate ILC2, and then adoptively transferred these cells into Rag1-/- Il2rg-/- 
hosts, which have no adaptive immune cells nor innate lymphocytes. At day 3 
post-transfer, I isolated lymphocytes from mLN, siLP and cLP to examine the 
frequencies of transferred ILC2. I observed that WT ILC2 efficiently migrated to 
gut-draining LN and LP of both small and large intestine, and were abundantly 
represented in cLP tissue (Fig. 5.9A and B). In contrast, Itk-/- ILC2 migration was 
greatly impaired to all intestinal tissues compared to WT ILC2 (Fig. 5.9A and B). I 
also analyzed the expression levels of CCR9 and integrin α4β7 on transferred 
WT and Itk-/- ILC2 in siLP and cLP. Although CCR9 expression was reduced on 
siLP of Itk-/- ILC2, no other differences between WT and Itk-/- transferred ILC2 in 
were observed (Fig. 5.9C and D). Taken together, these data show that a 
deficiency in ITK leads to a cell-intrinsic defect in a tissue maintenance of ILC2 in 
the gut tissue, but that the mechanism of this impaired migration is unlikely to be 
due to impaired gut-homing receptor expression. 
 
G. Itk deficiency affects intestinal tissue integrity 
The results thus far indicated that the absence of ITK caused an intestinal ILC2 
defect. Given the reparative function of intestinal ILC2 in helminthic infection or 
autoimmune disease conditions (Bruce et al., 2017; Moro et al., 2009; Neill et al., 
2010; Price et al., 2010; Tait Wojno and Artis, 2016), I considered whether the 
intestinal ILC2 defect in Itk-/- mice affected gastrointestinal tissue integrity and  
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Figure 5.9. Itk-deficient ILC2 are impaired in repopulation of the intestine 
(A-D) Lineage-depleted BM cells were cultured with IL-2, IL-7, and IL-33 in the 
presence of RA plus TGF-β for 3 d and then enriched by using CD25 
MicroBeads. Cultured and enriched cells were adoptively transferred to Rag1-/- 
Il2rg-/- hosts, and the proportions of ILC2 in the mLN and small or large intestinal 
LP were examined at D3 post-transfer (A). Compilation of data from 5 mice per 
genotype (B). The expression of CCR9 and integrin α4β7 on transferred WT and 
Itk-/- ILC2 in the small intestinal LP was examined (C). Compiled MFIs are shown 
(D).   
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repair from intestinal damage. To test this, I challenged WT and Itk-/- mice with 
3.0% DSS-dissolved water for 5 d to induce intestinal damage, and then restored 
normal drinking water for an additional 10 d to monitor intestinal tissue repair 
(Fig. 5.10A). As shown in Fig. 5.10B, DSS-treated WT mice exhibited weight loss 
beginning at day 5 post-treatment and then recovered and gradually regained 
lost weight starting at day 9 (Fig. 5.10B). In contrast, Itk-/- mice displayed an 
immediate weight loss beginning on day 1, and showed a continuous weight loss 
during the recovery period (D6 to 15) (Fig. 5.10B). Failure to recover from the 
DSS-induced damage was ultimately fatal in Itk-/- mice (n=7.0, mean survival = 
11.0), while DSS-treated WT mice showed no lethality (n=6) (Fig. 5.10C). 
Consistent with these data, histological analysis of DSS-treated Itk-/- colons at D7 
post-treatment revealed more cellular infiltrates than seen in WT colon histology 
at D7 (Fig. 5.10D), and the length of Itk-/- colons (n=5) was shorter compared with 
WT colons (n=5), indicating more severe inflammation in the colons of Itk-/- mice 
(Fig. 5.10E). As expected, the frequencies of ILC2 in Itk-/- colonic LP was greatly 
reduced in DSS-treated Itk-/- mice compared to controls, as I observed under 
steady-state conditions (Fig. 5.10F). The role of ILC2 in the maintenance of 
tissue integrity is mediated by effector cytokines produced by these cells, such as 
IL-5 and IL-13, which induce tissue repair, mucus production, and goblet cell 
hyperplasia (McKenzie et al., 1998; Price et al., 2010; Xu et al., 2017). Therefore, 
I performed intracellular cytokine staining for IL-5 and IL-13 with isolated colonic 
LP lymphocytes from DSS-treated WT and Itk-/- mice at D7 post-treatment. As 
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shown in Fig. 5.10G and H, IL-5 and IL-13 production from cLP ILC2 in Itk-/- mice 
was significantly reduced in comparison to the production from WT cLP ILC2.  
      To independently test whether Itk-/- mice had impaired intestinal tissue 
integrity, I administered FITC-dextran to untreated WT and Itk-/- mice via oral 
gavage, and compared the levels of serum FITC-dextran after 4 h as an indicator 
of intestinal permeability. Consistent with the findings in the DSS-damage model, 
I observed a higher level of FITC-dextran in the serum collected from Itk-/- mice 
than WT mice (Fig. 5.10I). These data strongly suggest that ITK deficiency, 
associated with the ILC2 defect in the colon, leads to impaired intestinal integrity 
under steady-state conditions, as well as in response to intestinal damage. 
 
H. IL-2 complex injection restores ILC2 numbers in the intestines of Itk-
deficient mice 
The data outlined above indicated a defect in gut-homing migration of ILC2 in Itk-
/- mice. I considered whether this defect might be due to impaired ILC2 
homeostasis in the gut, as a component of the failure to observe high numbers of 
Itk-/- ILC2 in the intestinal tissues of Rag-/-Il2rg-/- mice after adoptive transfer. 
Specifically, I considered whether the ITK deficiency might contribute to a defect 
in ILC2 cell survival in the gut as a result of a reduced IL-2 production by Itk-/- T 
cells. To test this hypothesis, I mixed IL-2 and anti-IL-2 mAb (JES6-1) to make 
IL-2 complexes (IL-2c), and injected these complexes daily into WT and Itk-/-  
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Figure 5.10. Itk-deficient mice have impaired intestinal tissue integrity  
(A-C) 3.0% DSS-dissolved water was given to WT and Itk-/- mice for 5d and then 
changed to normal drinking water for 10d (A). Weight changes were monitored 
daily (B) and the survival of WT and Itk-/- mice from D0 to D15 is shown (C). (D-H) 
WT and Itk-/- mice were treated with 3.0% DSS water for 7d and histology of distal 
colon was examined (D). The length of colons from each group was measured 
(E) and colon ILC2 proportions were examined at D7 (F). Isolated lymphocytes 
from colon LP of WT and Itk-/- mice at D7 were stimulated with PMA and 
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ionomycin for 5 h and stained for IL-5 and IL-13. Data show cells gated on 
lineage-negative CD90+ Sca-1+ cells (G). Complied data are shown (H). (I) 
Intestinal permeability of WT and Itk-/- mice at steady-state was measured by 
assessing serum levels of FITC-dextran 4 h after oral administration.   
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mice. After 4 days, I analyzed ILC2 in the intestines. As reported previously 
(Roediger et al., 2013; 2015; Seehus et al., 2017), IL-2c injection into WT mice 
increased the frequencies of ILC2 (CD90+ Sca-1+) in siLP and cLP compared 
with PBS-injected control mice (Fig. 5.11A and B). Surprisingly, IL-2c injection 
into Itk-/- mice showed a profound effect on ILC2, leading to complete restoration 
of ILC2 proportions in the siLP and cLP, to a level similar to that seen in IL-2c-
treated WT mice (Fig. 5.11A and B). 
      To determine whether restoration of ILC2 in the intestine of Itk-/- mice by IL-2c 
improved the responses of these mice to intestinal tissue damage, I treated mice 
with DSS (Fig. 7B). Although IL-2c treatment provided a marginal improvement in 
weight loss after DSS-induced damage in WT mice, IL-2c-treated Itk-/- mice were 
markedly improved compared to controls (DSS but no IL-2c; Fig. 8C). In fact, IL-
2c treatment of Itk-/- mice restored their ability to respond to intestinal tissue 
damage to that of control-treated WT mice. 
      These findings suggested that Itk-/- intestinal ILC2 might have impaired 
survival potential, leading to their reduced numbers and inability to expand in 
numbers following virus-induced or chemical-induced intestinal tissue damage. 
To assess this, I first examined Annexin V staining on siLP and cLP ILC2, before 
and after IL-2c treatment. After IL-2c treatment, we observed increased Annexin 
V on Itk-/- ILC2, while all other populations were similar (Fig. 8D-E). These data 
indicate that the increased numbers of ILC2 in IL-2c-treated Itk-/- mice are 
undergoing a higher rate of apoptosis compared to all other ILC2 populations. As 
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IL-2 stimulation of T cells is known to upregulate Bcl-2 (Gómez et al., 1998; 
Miyazaki et al., 1995), Bcl-2 levels under steady-state conditions (Fig. 8F-G). In 
response to IL-2c, Bcl-2 levels in Itk-/- ILC2 increased substantially, and achieved 
levels comparable to those seen in the respective WT ILC2 populations. 
Collectively, these data support the conclusion that the defect in intestinal ILC2 in 
Itk-/- mice results from impaired ILC2 survival in the intestinal environment.  
 
J. Discussion to Chapter V 
In this study, I show that ITK deficiency specifically affects tissue homeostasis of 
ILC2 in the intestine, but not ILC2 residing in other tissues or other innate ILC 
subsets, such as ILC1 and ILC3. As reported previously, TCR signaling-
associated genes and cytokine receptors are known to be upregulated in ILC 
precursors during their early development upon the expression of T cell lineage 
transcription factors, e.g. TCF-1, GATA-3, and Bcl11b (Constantinides et al., 
2014; Harly et al., 2018; Hoyler et al., 2012; Klose et al., 2014; Yang et al., 
2015). However, the role of these genes in mature ILC positioned in the 
peripheral tissues has not been well characterized. Given CD25 expression 
among ILCs and the responsiveness to IL-2 (Artis and Spits, 2015; Klose and 
Artis, 2016; Roediger et al., 2015; Seehus et al., 2017), the function of ITK in 
ILC2 might be involved in IL-2-associated ILC2 homeostasis in the periphery. In 
CD4+ T cells, ITK is required for TH2-mediated response, which is dependent on  
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Figure 5.11. IL-2 complex injection restores ILC2 numbers in the intestine and 
ameliorates DSS-induced weight loss in Itk-/- mice 
(A-C) PBS or IL-2 and anti-IL-2 mAb complexes (IL-2c) were injected daily IP for 
4 d, and the proportions of gut ILC2 (CD90+ Sca-1+) from the lamina propria of 
small and large intestines were examined after gating on lineage-negative cells 
(A). Compiled gut ILC2 proportions (B) and numbers (C) from two independent 
experiments is shown. (D) PBS- or IL-2c-treated WT and Itk-/- mice were 
administered 3.0% DSS for 7 d, and weight was monitored daily. (E-H) The 
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expression of Annexin V (E) and Bcl-2 (G) in siLP and cLP ILC2 from PBS- or IL-
2c-treated WT and Itk-/- mice was examined. Compiled MFIs from two 
independent experiments are shown (F and H).  
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IL-2/STAT5-mediated signaling (Cote-Sierra et al., 2004; Miller et al., 2004). 
Supporting this notion, STAT5 deficiency affects GATA-3 expression in intestinal 
ILC2 while RORγt expression in ILC3 is largely normal (Villarino et al., 2017). 
      In response to viral infections, such as respiratory syncytial virus, rhinovirus, 
or influenza A virus, lung-resident ILC2 are activated via IL-25 or IL-33 (Chang et 
al., 2011; Gorski et al., 2013; Hong et al., 2014; Jackson et al., 2014; Monticelli et 
al., 2015; 2011). However, no studies have examined the changes in ILC2 
residing the intestine upon virus infection. However, considering the increase of 
IL-25-producing tuft cells to murine norovirus infection (Wilen et al., 2018), 
intestinal ILC2 would be likely to expand as to intestinal parasite infections, e.g. 
Heligmosomoides polygyrus and Nippostrongylus brasiliensis (Y. Huang et al., 
2015; Moltke et al., 2016). The role of intestinal ILC2 during pathogen infection is 
to promote intestinal epithelium integrity via IL-5, IL-13, and amphiregulin, which 
leads goblet hyperplasia and mucus production (Monticelli et al., 2015; Moro et 
al., 2009; Neill et al., 2010; Price et al., 2010). In consistent to these findings, Itk-/- 
mice lacking ILC2 in the intestine displayed more severity to DSS-induced 
intestinal tissue damage, and the intestinal tissue permeability of Itk-/- mice were 
greatly increased in a steady-state (Fig. 5.10). Although the severity to DSS-
induced damage could be affected by a potential defect in T cells due to ITK 
deficiency, DSS colitis is considered to be largely dependent on innate immunity 
(Chassaing et al., 2001), and the onset of weight loss in Itk-/- mice to DSS 
treatment is immediate (D1 of post-treatment, Fig. 5.10B), which place a less 
 136 
weight on the contribution of T cells to disease progression in DSS-treated Itk-/- 
mice. 
In the present study, I showed IL-2/anti-IL-2 complex injection restores 
intestinal ILC2 defect in Itk-/- mice while IL-33 injection failed to exert such effect. 
As I observed a comparable proliferation of both WT and Itk-/- ILC2 to IL-33 in 
other organs in vivo, it is possible that an initial number of gut ILC2 in Itk-/- mice 
too low to make a robust induction in the intestinal lamina propria. In contrast, Itk-
/- ILC2 in the intestine showed an extensive expansion upon IL-2 complex 
injection, even more drastically comparing to intestinal WT ILC2 to IL-2 complex 
(Fig. 5.11A and B). Previous reports showed that IL-2, a cytokine predominantly 
produced by CD4+ T cells, promotes the proliferation, expansion, and also 
effector function of ILC2, suggesting a reciprocal interaction between CD4+ T 
cells and ILC2 (Mirchandani et al., 2014; Oliphant et al., 2014; Roediger et al., 
2015; 2013). As we observed comparable gut-homing receptor expression on 
both WT and Itk-/- ILC2, the intestinal ILC2 defect in Itk-/- mice is unlikely to be 
accounted for by a cell-intrinsic migration defect, despite the reduction in Itk-/- 
ILC2P seen three days after transfer of ILC2 precursors into Rag1-/- Il2rg-/- hosts. 
Instead, I favor a cell-intrinsic role for ITK in promoting intestinal ILC2 survival. As 
we have also observed a steady-state reduction in the numbers of gut-resident T 
cells, both CD4+ and CD8+, in Itk-/- mice (Fig. 4.6C and D in Chapter IV), we 
speculated that the availability of IL-2 from T cells in the gut microenvironment of 
Itk-/- mice would likely be limited leading to disruption of ILC2 tissue homeostasis. 
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As IL-2 is a known pro-survival signal for T cells, we considered that the same 
might be the case for ILC2. Supporting this notion, siLP ILC2 frequencies in Rag-
/- mice is lower than that seen in WT mice, indicating that gut-resident 
lymphocytes, most likely T cells, are important for ILC2 gut homeostasis 
(Spencer et al., 2014). Furthermore, the extensive expansion of Itk-/- ILC2 
observed following IL-2c injection is likely due to reduced gut-resident T cell 
numbers in Itk-/- mice providing less competition for the injected IL-2. 
      Our data support a role for IL-2-mediated signaling in the survival and 
persistence of intestinal ILC2. One likely mechanism is IL-2-induced activation of 
STAT5 leading to transcription of the STAT5 target gene Bcl-2 (Shenoy et al., 
2014; Villarino et al., 2017). Although IL-15 can also affect cell survival of ILC via 
STAT5, IL-15-mediated signaling is not required for the homeostasis of ILC2 
(Villarino et al., 2017). Of note, CD122 expression level in ILC2 is relatively lower 
than the level in ILC1 and ILC3, indicating STAT5 signaling in ILC2 would be 
more dependent on IL-2 (Robinette et al., 2017). Interestingly, Villarino et al. 
suggested that this loss of intestinal ILC2 in Stat5-deficient mice is due to defects 
in later development, i.e. tissue homing or peripheral homeostasis, not due to 
defects in ILC2 progenitor (Villarino et al., 2017). These data indicate that ITK-
associated defect in ILC2 could be related to an altered IL-2/STAT5 signaling. 
Consistent to this, Itk-/- ILC2 displayed reduced Bcl-2 expression in response to in 
vivo IL-2 stimulation (Figure 5.11G and H) as similar to reduced Bcl-2 expression 
in Stat5-deficient ILC2 (Villarino et al., 2017). Together with the effect of IL-2 
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complex injection in Itk-/- ILC2, I propose that ITK-associated defect in intestinal 
ILC2 is due to IL-2 availability in the microenvironment and also due to an 
impaired cell survival associated with Bcl-2. 
      Overall, I show that ITK regulates ILC2 tissue homeostasis in the intestine, 
and thereby affecting intestinal epithelium barrier integrity. The data shown in the 
present study suggest that ITK deficiency may affect the severity of enteric 
pathogen infection or inflammatory bowel disease via ILC2-mediated tissue 
homeostasis.  
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Previous studies have indica(Gibson et al., 1996; Heyeck and Berg, 1993; Shan 
and Wange, 1999). While ITK recruitment to the signaling complex is dependent 
on LAT phosphorylation by ZAP-70 (Shan and Wange, 1999; W. Zhang et al., 
1998), LCK is known to directly activate ITK via the phosphorylation of the 
conserved activation loop Tyr-511 residue (Gibson et al., 1996; Heyeck et al., 
1997). In the TH polarization experiments in Chapter III, TCR transgenic CD4+ T 
cells (B10.A 5C.C7) were stimulated with an anti-CD3 monoclonal antibody, not 
with a cognate antigenic peptide (moth cytochrome C/I-EK). Although an anti-
CD3 stimulation is not likely to activate CD4 or CD8 co-receptor, LCK can be 
recruited to the TCR complex without co-receptors (Casas et al., 2014). In 
addition, TCR engagement alone can initiate the formation of immunological 
synapse (Locksley et al., 1993; Schilham et al., 1993; Van Laethem et al., 2007), 
which enables the exclusion of negative phosphatases, such as SH2 domain-
containing phosphatase 1 (SHP-1) and CD45, from the TCR microclusters. 
These spatial changes in the molecules will trigger LCK activation to 
phosphorylate of CD3 ITAM motifs and ZAP-70 and eventually lead to ITK 
activation. However, the status or the kinetics of ITK activation responding to 
either anti-CD3 stimulation or cognate peptide stimulation were not tested at the 
initiation of TCR engagement in this thesis. 
      While PRN694-mediated ITK and RLK dual inhibition leads to an impairment 
in the differentiation of all TH subsets, the potency of inhibition was most effective 
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in TH1 differentiation comparing with the potency of inhibition in TH17 and TH2 
differentiation. This mode of inhibition is consistent with the previous in vivo data 
showing that Itk-/- Rlk-/- mice are impaired to mount TH1-mediated protective 
response to T. gondii infection while TH2-mediated response to S. mansoni was 
not affected (Schaeffer et al., 2001; 1999). However, this pattern of inhibition 
contrasts to the effect of Itk deficiency on different ILC subsets. As shown in 
Chapter V, Itk-deficient mice showed a defect in ILC2, which is a counterpart of 
TH2 cells, but not in other ILCs. This discrepancy might be due to the difference 
in the target of inhibition as PRN694 inhibits both ITK and RLK in while Itk 
deficiency only affects ITK. Furthermore, the data shown in Figure 5.11 suggest 
that the effect of Itk deficiency on ILC2 is associated with IL-2-mediated survival, 
not in their effector function. As Itk-/- mice showed a comparable lung ILC2 cell 
number in response to papain challenge (Gomez-Rodriguez et al., 2016), ITK 
inhibition using PRN694 administration also might not affect type 2 immunity in 
the intestine, such as Nippostrongylus brasiliensis or Trypanosoma cruzi 
infection. However, Itk-/- mice failed to induce gut ILC2 proliferation while lung 
ILC2 number was comparable, which implies that Itk deficiency affects the 
maintenance of the pool of intestinal ILC2. 
      The results from in vitro TH polarization experiment led to us to examine the 
efficacy of PRN694 treatment in TH1-mediated colitogenic inflammation in Rag2-/- 
mice. As expected, PRN694 administration prevented colitis disease progression 
in colitogenic T cell-transferred Rag2-/- mice. Interestingly, the number of CD4+ T 
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cells in the colon of PRN694-treated hosts was markedly reduced comparing to 
CD4+ T cell number in the colon of vehicle-treated hosts. As I observed the defect 
in CD8+ T cell migration to the intestine of naïve and MHV68-infected Itk-/- mice 
(Fig. 4.4 and 4.6 in Chapter IV), these results support that ITK is important for 
both CD4+ and CD8+ T cell migration to the intestine in a steady-state and in an 
inflammatory setting. Considering the effect of Itk deficiency on ILC2 and 
intestinal integrity, it is possible that PRN694 administration can affect ILC2 in the 
intestine. Although we have not examined the effect of PRN694 on intestinal 
ILCs in Rag-sufficient or -deficient mice, the effect of ITK/RLK dual inhibition will 
be more broad owing to the fact there are ILC populations that express RLK, 
such as ILC1 or ILC3 (www.immgen.org). Future studies are warranted to 
examine the changes of ILCs upon PRN694 treatment in a steady-state in Rag-
deficient mice, and these changes in ILC would affect the susceptibility to 
intestinal tissue damage. Although I could not assess the effect of PRN694 in 
TH17 cells in vivo in TH1-skewed colitis model, a recent study from Fuhriman et 
al. suggested that PRN694-mediated ITK and RLK inhibition also effectively 
reduced the severity of TH17-mediated psoriatic response in the skin and 
impaired T cell infiltration in skin lesion in mice (Fuhriman et al., 2018). 
Therefore, together with the inhibitory effect of PRN694 on both TH1 and TH17 in 
vivo, the data presented here provide strong support for the development of a 
strategy to target ITK and RLK as a potential therapeutic agent for an 
inflammatory bowel disease and skin psoriasis.  
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      In colon IEL CD4+ T cells from PRN694-traeted hosts at 7 weeks of post-
transfer, the expression of gut-homing receptors, such as integrin α4β7 and 
CCR6, was lower than IEL CD4+ T cells from the colon of vehicle-treated hosts. 
Despite of a marginal expression of these receptors in CD4+ T cells from other 
tissues (e.g. mLN or spleen), it is plausible that the expression level of these 
receptors would be different at the early stage of T cell transfer. In addition to the 
expression of gut-homing receptors, P-selectin binding affinity of TH1 and TH17 
cells was abrogated when PRN694 was treated. As PRN694-treated CD4+ T cells 
showed an impaired P-selectin binding, MHV68-specific CD8+ T cells from the 
small intestine of Itk-/- mice also displayed an abrogated binding to P-selectin 
ligand during viral infection (data not shown). However, P-selectin binding of Itk-/- 
ILC2 or PRN694-treated ILC2 ex vivo were not tested ex vivo in this thesis. Of 
note, P-selectin binding of PSGL-1 is determined by the status of glycosylation 
(Carlow et al., 2009). Therefore, it will be interesting to investigate how ITK 
inhibition affects the expression or the enzymatic activity of PSGL-1 glycosylation 
enzymes in T cells and ILC subsets.   
      I investigated a function of Tec kinase ITK in T cells in the intestine and anti-
viral immune response to gammaherpesvirus infection. Unlike a normal 
protective response in the spleen in both WT and Itk-/- mice, mice lacking ITK 
failed to mount a protective response to control MHV68 viral replication in the 
intestine. Impaired anti-viral immune response in the intestine of Itk-/- mice was 
associated with the defect in CD8+ T cell migration to the intestine during 
 144 
infection. Intriguingly, Itk-/- mice show a substantial reduction in gut-resident T cell 
population in the intestinal tissue. In consistent to an impaired gut-homing, the 
expression of gut-homing receptors in Itk-deficient CD8+ T cells was greatly 
reduced. As reported previously (Khanna et al., 2003; Knickelbein et al., 2008; 
Liu et al., 2001; Sheridan et al., 2014), tissue-resident CD8+ T cells play an 
important role in a latent virus infection or an anti-viral immunity upon reinfection. 
This notion supports that the defect in gut-resident T cells is associated with a 
spontaneous lethality in MHV68-infected Itk-/- mice. However, the defect in gut-
resident T cells alone does not explain the cause of mortality in Itk-/- mice during 
late phase of infection despite of a high viral copy number in the intestine of Itk-/- 
mice from early phase of infection. Although Itk deficiency does not affect 
memory T cell response to LCMV infection (Atherly et al., 2006a), a high viral 
copy number in the intestine of MHV68-infected Itk-/- mice in the late phase of 
infection could be associated with an impaired tissue-specific memory T cell 
response against a latent type of virus, such as MHV68. Interestingly, the 
replication of MHV68 in the intestine of Itk-/- mice was consistently high at both 
early and late timepoints of infection. This indicates that the function of ITK is 
important in both migration and anti-viral CD8+ T cell response at an early phase 
of infection in the intestinal mucosa.  
 
      In the absence of ITK, CD8+ T cells showed an impaired expression of gut-
homing receptors in response to RA and TGF-β. Although IRF4 forced 
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expression restored the expression of homing receptors and the migration to the 
gut, it is still not clear whether an impaired gut homing in Itk-/- CD8+ T cells can be 
fully explained by these receptors. We previously showed that the ablation of ITK 
in Ctla4-/- T cells blocks the CD28-dependent trafficking of self-reactive T cells to 
the peripheral tissues (Jain et al., 2013). From the inhibited of P-selectin binding 
by PRN694, I suspect that ITK can also affect transendothelial migration of both 
CD4+ and CD8+ T cells. Also, our preliminary data shows that P-selectin binding 
of CD8+ T cells are also regulated by CD28 costimulation. Future studies are 
warranted to investigate how ITK-mediated TCR downstream signaling affects 
CD28 downstream signaling and regulates transendothelial migration of T cells 
via the interaction with P-selectin and other molecules. 
      During MHV68 latency in WT and Itk-/- mice, LPS-derived injection resulted in 
an acute mortality of virus-infected Itk-/- mice, but not in virus-infected WT mice or 
LPS-injected WT and Itk-/- mice with no infection. Since the time leading to the 
mortality was relatively short (Day 1 to 3), the effect of viral reactivation induced 
by LPS injection is not sufficient to explain such an acute phenotype. Based on a 
high incidence of mortality during the late latency (D90 or 100) comparing with 
the early latency (D30 or 60), the length of time that exposed to viral persistence 
may relate with the susceptibility to LPS-induced mortality in the Itk-/- infected 
hosts. Given role of ILC2 in intestinal tissue repair, gut ILC2 defect in Itk-/- mice 
may contribute to LPS-induced gut pathology during MHV68 latency. However, I 
could not observe any noticeable pathology when the same dose of LPS was 
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challenged to either uninfected WT or Itk-/- mice. One plausible explanation is that 
a persistent viral replication in the intestine of Itk-/- mice during latency causes a 
chronic tissue damage that increases intestinal permeability and susceptibility to 
viral reactivation. Although naïve Itk-deficient mice display increased intestinal 
permeability without viral infection (Fig. 5.8I), future studies are warranted to 
determine the changes in intestinal tissue integrity of Itk-/- mice as latency 
progresses.  
      ITK is expressed in not only T cells but also γδ T cells and NKT cells, and 
these innate lymphocytes are also residing in the intestinal epithelium (Fan and 
Rudensky, 2016). Although I could not find any overrepresentation of these 
innate lymphocytes in the intestine as reported previously (Felices et al., 2009), 
Itk-deficient γδ T cells produce an excessive amount of IL-4 in other peripheral 
organs, such as thymus, spleen, and liver. Interestingly, Reese et al. reported 
that helminth infection during MHV68 latency reactivates virus replication in IL-4-
dependent manner (Reese et al., 2014). Owing to a reduction in IEL γδ T cells in 
Itk-deficient mice, γδ T cell-derived MHV68 reactivation is not likely, and the 
MHV68 replication in the spleen is controlled despite of an enriched γδ T cells.   
      This study suggests a new mechanistic insight in how TCR signaling via ITK 
and IRF4 regulates the expression of gut-homing receptors, thereby affecting 
gut-homing potential of T cells. Although there is a functional gap between a Tec 
kinase ITK and a transcription factor IRF4, IRF4 was one of the most 
downregulated genes in Itk-deficient thymocytes (Nayar et al., 2012), and both 
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gene expressions are sensitive to TCR signaling strength (Yao et al., 2013). 
Based on a known function of ITK in TCR downstream signaling, ITK contributes 
to regulate the magnitude of calcium signaling in T cells by modulating PLCγ1 
activity, which directly leads to NFATc1 activation. Supporting this notion, 
NFATc1 regulates IRF4 gene expression by binding to multiple Irf4 loci 
suggesting a possible molecular link between ITK-IRF4 axis mediated by 
NFATc1 activity (Klein-Hessling et al., 2017). 
      In addition to the similarity in the mode of expression upon TCR stimulation, 
both Itk-/- and Irf4-/- CD8+ T cells share an impaired responsiveness to induce a 
gut-homing receptor, such as CD103. Recent studies indicate IRF4 and other 
binding partners, e.g. BATF or JunD, co-binds to the genes encoding gut-homing 
receptors, such as Itgae, and Ccr9, in CD8+ T cells (Iwata et al., 2017; Kurachi et 
al., 2014; P. Li et al., 2012). Consistent to this data, a recent study support a 
functional correlation between IRF4 and intestinal immunity to enteric bacterial 
infection (Guérin et al., 2018). Interestingly, Batf-deficient mice also have a 
phenotypic similarity with Itk-deficient mice in their tissue-resident T cells in the 
intestine (Wang et al., 2013). Although I have not tested if an enforced 
expression of BATF exerts a same effect as IRF4 does in Itk-/- CD8+ T cells, 
future will be required to examine how TCR downstream signaling mediated by 
ITK correlates with a BATF-IRF4 complex and a balancing role of this complex in 
the regulation of gut-homing receptor expression under a steady-state or an 
enteric pathogen infection. 
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      In the result of IRF4 overexpression in Itk-deficient CD8+ T cells, the defect in 
gut tissue homing ability in vivo is efficiently restored with their homing receptor 
expression in uninfected naïve hosts. However, it is still unclear IRF4 
overexpression in Itk-deficient CD8+ T cells will also contribute to an enhanced 
anti-viral CD8+ T cell response. From the previous reports using Irf4fl/fl mice, IRF4 
deficiency results in limited effector and memory responses to LCMV infection, 
which eventually leads to viral persistence (Grusdat et al., 2014). In Listeria 
monocytogenes and influenza viral infection setting, the effector function of CD8+ 
T cells is progressively reduced at late phase of infection (Man et al., 2013; 
Raczkowski et al., 2013). These results suggest that a sustained lRF4 
expression in CD8+ T cells is important for the control of viral replication during a 
long latency. The requirement of ITK activity to induce IRF4 at different phases of 
viral infection will necessitate further studies as IRF4 expression is changing 
during viral infection and their cooperativity with other transcription factors will be 
dynamic (Man et al., 2017; Nayar et al., 2014). 
      In MHV68 infection, CD8+ T cells are necessary and also sufficient to 
eliminate acute viral replication in the absence of CD4+ T cell help (Braaten et al., 
2005). However, anti-viral CD4+ T cells are important for a long-term viral control 
of MHV68 in the lung (Cardin et al., 1996). As we observed the restoration of 
intestinal ILC2 deficit by IL-2 and anti-IL-2 complex (JES6-1A12) administration, 
it is plausible that CD4+ T cells is playing a critical role in the tissue maintenance 
of gut CD8+ T cells via IL-2 production. Although we could not precisely test the 
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effect of IL-2 complex on CD4+ or CD8+ T cells due to a known preferential 
binding of JES6-1A12 clone to Treg over the conventional T cells (Boyman et al., 
2006; Spangler et al., 2015; Webster et al., 2009), future studies are required to 
examine if an adoptive transfer of virus-specific CD4+ T cell transfer or an 
injection of IL-2 complex with S4B6 clone to Itk-/- mice will lead to the recovery of 
gut CD8+ T cell deficit during viral infection.  
      I examined a function of Tec kinase ITK in type 2 innate lymphoid cells and 
intestinal tissue homeostasis. I showed that ITK deficiency impacts on ILC2 in 
the intestine, but not in other innate lymphoid cell subsets. This phenotype in 
innate lymphoid cells from Itk-/- mice corresponds to the upregulated gene 
expression in ILC2 (Shih et al., 2016) (www.immgen.org). During early ILC 
development, a set of TCR-associated genes are getting expressed 
(Constantinides et al., 2014; Yang et al., 2015; 2013), but a functional role of 
these genes in mature ILC in mucosal tissues has not been fully characterized. I 
could not find any evidence to conclude that ITK deficiency affects the 
expression of ILC2-associated cytokine receptors and gut-homing receptor 
molecules. Despite of a comparable gut-homing receptor expression on ILC2, the 
migration of Itk-/- ILC2P to the small intestine was greatly impaired, and this 
directed us to examine possible factors that affect tissue homeostasis of ILC2 in 
the intestine.  
      Consistent to the lack of intestinal ILC2, Itk-deficient mice shows an 
increased permeability in a steady-state and displayed more severity to DSS-
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induced tissue damage in the colon. Based on the data shown in Chapter IV, ITK 
deficiency in mice affects both gut-resident T cells and intestinal ILC2 
homeostasis. However, based on an immediate response upon DSS treatment 
and a low cellularity of gut T cells in Itk-/- mice, the contribution of T cells on this 
phenotype in Itk-/- mice is less likely. In a range of virus infections, ILC2 promotes 
lung epithelial tissue damage repair (Monticelli et al., 2015; 2011; Stier et al., 
2016). As a previous study reported comparable changes in lung ILC2 from WT 
and Itk-/- mice upon papain challenge (Gomez-Rodriguez et al., 2016), I could not 
find any differences in lung ILC2 between WT and Itk-/- mice after intranasal 
MHV68 inoculation. In contrast to this comparable lung ILC2 response, Itk-/- ILC2 
failed to proliferate after intraperitoneal MHV68 inoculation in the intestine 
comparing WT intestinal ILC2. These data suggest that ILC2 defect in the 
intestine of Itk-/- mice may cause more severe intestinal pathology in response to 
enteric pathogen-induced tissue damage. 
      In contrast to a failure of IL-33 to induce intestinal ILC2 proliferation in Itk-/- 
mice, IL-2 complex treatment to Itk-/- mice elicited an extensive increase in 
intestinal ILC2. As shown previously, IL-2 administration leads to the proliferation 
of ILC2 and eosinophilia in the lung (Roediger et al., 2015; Van Gool et al., 
2014). Although IL-2 treatment induces ILC2 expansion in the lung, IL-2 signaling 
alone is insufficient to affect an effector function of ILC2, such as IL-5 or IL-13 
production (Roediger et al., 2015). Interestingly, IL-2 cooperatively acts with IL-
33 to enhance the cytokine-induced response by ILC2 to external stimuli, such as 
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IL-25, IL-33, and TSLP, and IL-2 signaling in ILC2 is mediated by STAT5 
(Camelo et al., 2017; Molofsky et al., 2015). While Itk deficiency does not affect 
IL-33-induced signaling in ILC2, Itk-deficient ILC2 are impaired in the expression 
of Bcl-2 and CD25. Furthermore, a recent study reported that IL-2 or 
constitutively active STAT5 restored a defect in effector function of Itk-/- TH9 cells, 
which have a functional similarity with ILC2 (Gomez-Rodriguez et al., 2016). 
These indicate a cell-intrinsic impairment in Itk-/- ILC2 is associated with the 
homeostasis and survival related with IL-2. In addition to a cell-intrinsic defect in 
IL-2 signaling in ILC2, Itk-deficient ILC2 will be likely to have a reduced 
availability of IL-2 in the intestine possibly due to a reduced CD4+ T cell number. 
In the lung, the primary cellular source of IL-2 is known to be CD4+ T cells and 
ILC3 (Roediger et al., 2015). However, it remains elusive whether ILC3 can 
produce a comparable amount of IL-2 as CD4+ T cells do in the intestinal 
epithelium. Owing to a comparable number of intestinal ILC3 from Itk-/- intestine, it 
is more likely that CD4+ T cell defect in Itk-/- mice would be more critical to ILC2 
tissue homeostasis.   
      To acquire an effector function, ILC2 utilize the signaling components of 
innate immune cells, e.g. MyD88 or TRAF6, in response to IL-25 or IL-33, which 
all leads to NF-κB activation (Alinejad et al., 2017; Liew et al., 2010). On the 
contrary, the cytokine response by ILC2 to IL-2, IL-7, or TSLP, is regulated via 
STAT5 phosphorylation. Given role of NFAT and AP-1 on IL-2-mediated 
signaling in T cells (Hermann-Kleiter and Baier, 2010), ITK activity may be 
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required to maintain a certain level of NFAT and/or AP-1 in ILC2. Supporting this 
notion, PKC-θ activation is important in TH2 and ILC2, which is known to directly 
regulate NFAT and IRF4 downstream signaling (Madouri et al., 2017).  
      In addition to the upregulation of these components, ITK downstream 
signaling in ILC2 may be involved in the expression of negative regulator that 
sustains an optimal level of activation. CISH, a member of suppressor of cytokine 
signaling (SOCS) family, is induced by the TCR stimulation or the addition of IL-2 
in T cells (Jin et al., 2006; S. Li et al., 2000; Matsumoto et al., 1997; Yoshimura 
et al., 1995). Palmer et al. and the other group reported that CISH interacts with 
PLCγ1 and induces a proteasomal degradation via polyubiquitination in CD8+ T 
cells (Guittard et al., 2018; Palmer et al., 2015). Despite of the absence of TCR, 
CISH is highly expressed in ILC2 with ITK and PLCγ1, but not in other ILC 
subsets (www.immgen.org) (Shih et al., 2016). Based on a high level of CISH in 
Treg expressing CD25 (Chinen et al., 2016), it is plausible that ILC2 and Treg are 
utilizing CISH as a negative regulator to balance IL-2-mediated signaling. 
Interestingly, TSLP stimulation induces CISH via STAT5 phosphorylation 
(Rochman et al., 2010), and this might explain why Cish expression is 
maintained in high level in ILC2. Since TSLP is secreted from intestinal epithelial 
cells (Taylor et al., 2009), gut ILC2 is also expected to have a high expression of 
CISH, and this will lead to a more suppression of PLCγ1 in the intestinal 
microenvironment. Although the expression level of CISH in gut ILC2 from Itk-/- 
mice was not examined in this thesis, TSLP-induced CISH expression could 
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cooperate with Itk deficiency to further downregulate the PLCγ1 activity and the 
required gene expression for ILC2 survival (Fig. 6.1). However, future 
investigations are required to fully understand how ITK-mediated downstream 
signaling impacts on the survival of ILC2.   
 154 
 
 
Figure 6.1. A proposed model of the function of ITK and IL-2-mediated 
signaling in ILC2 
In WT ILC2 (left panel), ITK and PLCγ1 activates the downstream signaling, such 
as NFAT and NF-κB, to induce the expression of IL-2-related genes (e.g. CD25 
and STAT5) and ILC2 survival genes (e.g. Bcl-2) in the cooperation with IL-33 
signaling. This pathway also leads to the activation of a negative regulator, CISH, 
which induces a proteasomal degradation of PLCγ1 to maintain an optimal status 
of activation in ILC2. The expression of CISH can be upregulated by TSLP via 
STAT5, which results in more CISH-mediated PLCγ1 suppression in TSLP-
enriched gut microenvironment. In the absence of ITK in ILC2 (right panel), 
PLCγ1 activity will be greatly diminished, and this will lead to the downregulation 
of IL-2-associated signaling and ILC2 survival genes.   
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